



Journal of Enzyme Inhibition and Medicinal Chemistry

ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: https://www.tandfonline.com/loi/ienz20

Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition

Salwa Elmeligie, Asmaa M. Aboul-Magd, Deena S. Lasheen, Tamer M. Ibrahim, Tamer M. Abdelghany, Sohair M. Khojah & Khaled A. M. Abouzid

To cite this article: Salwa Elmeligie, Asmaa M. Aboul-Magd, Deena S. Lasheen, Tamer M. Ibrahim, Tamer M. Abdelghany, Sohair M. Khojah & Khaled A. M. Abouzid (2019) Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition, Journal of Enzyme Inhibition and Medicinal Chemistry, 34:1, 1347-1367, DOI: <u>10.1080/14756366.2019.1642883</u>

To link to this article: <u>https://doi.org/10.1080/14756366.2019.1642883</u>

9	© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.	+	View supplementary material 🕝
	Published online: 19 Jul 2019.		Submit your article to this journal 🛽 🖉
ılıl	Article views: 63	CrossMark	View Crossmark data 🗗

RESEARCH PAPER

OPEN ACCESS Check for updates

Taylor & Francis

Taylor & Francis Group

Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition

Salwa Elmeligie^a, Asmaa M. Aboul-Magd^b, Deena S. Lasheen^c, Tamer M. Ibrahim^d, Tamer M. Abdelghany^e, Sohair M. Khojah^f and Khaled A. M. Abouzid^{c,g}

^aPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt; ^bPharmaceutical Chemistry Department, Faculty of Pharmacy, Nahda University, Beni Suef, Egypt; ^cPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; ^dPharmaceutical Chemistry Department, Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, Egypt; ^ePharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt; ^fBiochemistry Department, Faculty of science, King Abdulaziz University, Jedda, Kingdom of Saudi Arabia; ^gDepartment of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt

ABSTRACT

In the designed compounds, either a biarylamide or biarylurea moiety or an N-substituted piperazine motif was linked to position 1 of the phthalazine core. The anti-proliferative activity of the synthesised compounds revealed that eight compounds (**6b**, **6e**, **7b**, **13a**, **13c**, **16a**, **16d and 17a**) exhibited excellent broad spectrum cytotoxic activity in NCI 5-log dose assays against the full 60 cell panel with Gl_{50} values ranging from 0.15 to 8.41 μ M. Moreover, the enzymatic assessment of the synthesised compounds against VEGFR-2 tyrosine kinase showed the significant inhibitory activities of the biarylureas (**12b**, **12c and 13c**) with IC_{50} s of 4.4, 2.7 and 2.5 μ M, respectively, and with 79.83, 72.58 and 71.6% inhibition of HUVEC at 10 μ M, respectively. Additionally, compounds (**7b**, **13c and 16a**) were found to induce cell cycle arrest at S phase boundary. Compound **7b** triggered a concurrent increase in cleaved caspase-3 expression level, indicating the apoptotic-induced cell death.

ARTICLE HISTORY

Received 1 April 2019 Revised 11 June 2019 Accepted 30 June 2019

KEYWORDS

Substituted phthalazines; VEGFR-2 kinase inhibitors; anti-proliferative; apoptosis

1. Introduction

Cancer is a leading cause of death worldwide¹. Epidemiological studies revealed that cancer accounts for one of every five deaths. Moreover, it is estimated that the annual number of deaths due to cancers will increase from 7.6 million in 2008 to 13 million in 2030².

Apoptosis, or programed cell death, plays a crucial role in maintaining the normal body health. However, malignant cells are generally less sensitive to these stresses and tend to evade apoptosis. Genetic regulation, initiation and effector mechanisms can be regarded as stages of apoptosis in its simplest model. Gamma and ultraviolet irradiation, anticancer drugs, deprivation of survival factors such as interleukin-1 (IL-1), or other cytokines that activate "death receptors" are considered as initiators of apoptosis³. Hence, the identification of apoptosis inducers has evolved as an attractive approach for the development of potential anticancer agents.

From another point of view, angiogenesis, the process of sprouting of new blood vessel formations from pre-existing ones, is also regarded as an important hallmark of cancer development. Vascular endothelial growth factor family (VEGFs) are known to be one of the key regulators of angiogenesis. Their biologic effects is exerted by binding to extracellular domain.

Multiple reports have detailed several small-molecule inhibitors of VEGFR-2 acting by binding to the ATP-binding site in the intracellular kinase domain resulting in diminished VEGF signal transduction, these inhibitors may be broadly categorised into two main types: type I; inhibitors represent ATP competitors that generally bind in or around the catalytic site of the kinase in its active conformation, in the region originally occupied by the adenine moiety of ATP⁴. On the other hand, type-II inhibitors stabilise the inactive conformation of the enzyme derived upon the movement of the DFG motif (i.e. Asp-Phe-Gly), hence, they exploit new interactions with the lipophilic pocket revealed in this new rearrangement⁵.

In the past few years, a number of VEGFR-2 inhibitors have proven success as targeted anticancer therapeutics. Among these is the 1,4-disubstituted phthalazine inhibitor, vatalanib. (PTK-787) (I) (IC₅₀ VEGFR-2 = 43 nM) (Figure 1)⁶.

The biarylurea-based inhibitor, sorafenib **(II)** (IC₅₀-VEGFR-2 = 90 nM) (Figure 1), has been approved for the treatment of advanced renal cell carcinoma⁷. Sorafenib was proved to suppress tumour proliferation, metastasis and angiogenesis; in addition, it was also found to be capable of inducing apoptosis, both *in vitro* and *in vivo*, in a host of cancer cells. However, the underlying mechanisms seemed to vary depending on cancer cell types^{8–10}. Interest in developing novel biarylurea-based VEGFR-2 inhibitors has been increasingly highlighted with the clinical success of sorafenib and its analogs, such as regorafenib **(III)**¹¹.

Moreover, the biarylamide, (AAL993) (IV), a hybrid-design type-II inhibitor derived from the type-I inhibitor vatalanib, was

 $^{
m C}$ 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CONTACT Khaled A. M. Abouzid abouzid@yahoo.com, Khaled.abouzid@pharma.asu.edu.eg Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

B Supplemental data for this article can be accessed here.



Figure 1. Structures of some known VEGFR-2 kinase inhibitors.

reported as a potent inhibitor of VEGFR family with VEGFR-2 $\rm IC_{50}$ of 23 $\rm nM^{12}.$

Also, telatinib (**V**), the furopyridazine derivative, emerged as a potent and orally available inhibitor of VEGFR-2, VEGFR-3 with $IC_{50}s$ 6 and 4 nM, respectively. It is currently in clinical trials for gastric and colorectal cancer¹³.

From another point of view, the piperazinyl moiety, the small rigid heterocyclic motif, has been successfully incorporated in several potent kinase inhibitors^{14–17}. The aryl piperazine-based derivative **(VI)** (Figure 1) was reported to exhibit potent single-digit nanomolar inhibitory activity on specific kinases^{18,19}.

2. Rationale and design

Based on the above findings, three series of phthalazine-based derivatives linked to a biarylamide (series A) or biarylurea tail (series B, C) at position 1 of the phthalazine core via an amino or ether linkage were designed and synthesised as potent anti-proliferative derivatives as well as apoptosis inducers in tumour cells. Different substitution patterns were introduced to the terminal aromatic ring aiming to better occupy the hydrophobic pocket revealed by the kinase in its DFG-out conformation (Figure 2). The design of these series was based on attaining new hybrid structures from sorafenib and vatalanib while maintaining the structure activity relationships as well as common pharmacophoric features shared by several VEGFR inhibitors which involve the following three features; (1) a flat heteroaromatic ring system to better occupy the ATP-binding region of the kinase, (2) a hydrogen bond donor-acceptor pair represented by the urea or amide moieties that usually form hydrogen bonds with Glu 885 and Asp 1046 residues, (3) a substituted terminal aryl moiety to occupy

the hydrophobic pocket revealed by the movement of the DFG motif of the kinase in its inactive conformation²⁰.

Furthermore, two other series of vatalanib analogs (series D, E) were designed having a 4-chloroaniline moiety at position 1 of the phthalazine and an anilino or phenoxy motif linked to the position 4 via a methylene spacer.

In addition, a sixth series of substituted piperazine-based derivatives (**series F**) was prepared as well, via linking the two major fragments: the phthalazine core recognised as a kinase-privileged fragment, to the piperazine moiety aiming to offer more rigidity and to facilitate deriving spatial–activity relationships¹⁵.

3. Chemistry

The pathways adopted for the synthesis of the new substituted phthalazine derivatives are depicted in Schemes (1-3). The key intermediate 1-aryl-3-(4-hydroxyphenyl)urea (1a-c), were prepared following the literature methods as illustrated in $(\text{Scheme 1}(a))^{21}$. On the other hand, cyclisation of the respective o-substituted benzoic acid derivative with hydrazine hydrate afforded the corresponding phthalazinones (2a,b). Chlorination of 2a,b with phosphorous oxychloride afforded the corresponding 1-chlorophthalazines (3a,b), which were used to prepare the target series of 1-substituted phthalazines via reaction with various nucleophiles. Thus, the reaction of **3a**,**b** with *p*-phenylenediamine in butanol via the displacement of the chloro atom of phthalazine with the suitable nitrogen nucleophile such as p-phenylenediamine afforded the N¹-(phthalazin-1-yl)benzene-1,4-diamines (4a,b). The latter compounds (4a,b) were further reacted with the respective benzoyl chloride in acetonitrile, in the presence of triethylamine to afford the target phthalazines bearing the biarylamide tail (5a-d)



Figure 2. Strategy for the design of the target compounds.

(series A). Moreover, the reaction of (4a,b) with different arylisocyanates in DMF yielded the biarylureas (6a-f) (series B). On the other hand, 1-aryl-3-(4-(4-substituted phthalazin-1-yloxy)phenyl)ureas (7a-f) (series C) were obtained via reacting the respective 1-chlorophthalazines (3a,b) with the appropriate intermediates (1a-c) in refluxing acetonitrile. This latter reaction proceeds via *ipso* addition by the nucleophile that gives an anion with a highly delocalised charge then followed by leaving of the chlorine atom of the respective 1-chlorophthalazines (3a,b) to afford the alkoxyphthalazines (7a-f). Refluxing the 1-chlorophthalazines (3a,b) with the appropriate piperazine derivative in ethanol yielded the target phthalazines bearing the substituted piperazinyl tail (8a-j) (series F) in good yields (Scheme 1(b)).

As for the synthesis of the biarylureas (**12a–c and 13a–c**) having a chloro substituent at 4 position of the phthalazine (Scheme 2), it was started by refluxing phthalic anhydride with hydrazine hydrate in acetic acid, followed by reflux with $POCl_3$ to give the 1,4-dichlorophthalazine intermediate (**10**). Thereafter, the target compounds (**12a–c and 13a–c**) were obtained in a manner similar to that adopted in Scheme 1(b).

Compounds (16a–d, and 17a,b) (series D, E) were synthesised via initial bromination of the key intermediate (14) with NBS in presence of catalytic amount of dibenzoyl peroxide. The reaction of the bromo derivative (15) with the respective aniline or phenol in acetone then afforded the titled compounds (Scheme 3).

4. Results and discussion

4.1. Biological evaluation

4.1.1. In vitro anticancer screening at full NCI 60 cell panel

Aiming to evaluate the general antitumour activity of the synthesised phthalazines, the structures of the final compounds were submitted to National Cancer Institute "NCI" (www.dtp.nci.nih.gov), Bethesda, Maryland, USA. *In vitro* NCI anticancer screening involves two-stage process, the first stage started with the evaluation of the selected candidates against the full NCI 60 cell lines panel representing leukaemia, non-small cell lung cancer, melanoma, colon, CNS, breast, ovarian, renal and prostate cancers at a single dose of $10\,\mu$ M. NCI selection is based on degree of structure variation and application of computer modelling techniques to prioritise compounds based on their ability to add diversity to the NCI small molecule compound collection.

Eighteen of the submitted phthalazines (**5b**, **5d**, **6b**, **6e**, **7b**, **7e**, **8a**, **8d**, **8f**, **8g**, **8h**, **8i**, **13a**, **13b**, **13c**, **16a**, **16d**, **and 17a**) were selected by NCI under drug discovery programme for screening against the full NCI 60 cell panel at single dose $10 \,\mu$ M. Among the investigated 18 compounds, eight compounds (**6b**, **6e**, **7b**, **13a**, **13c**, **16a**, **16d and 17a**) were selected by NCI for further screening at 5-log dose molar range due to their prominent cell growth inhibition against various cell lines.

4.1.1.1. Primary in vitro antineoplastic single-dose assay. Primary in vitro single-dose anticancer assay was evaluated against full NCI 60 cell panel. Results for each compound were presented as a mean graph of the growth per cent of the treated cells compared to the untreated control cells. Eight of the investigated phthalazine-based derivatives (6b, 6e, 7b, 13a, 13c, 16a, 16d and 17a) showed a distinctive pattern of sensitivity against various NCI cell lines (Tables S1 and S2 in Supplementary material). Thus, the biarylurea-based derivatives having a terminal 4-chloro substituent (6b, and 6e) exhibited remarkable broad spectrum cell growth inhibition above 90% against various cell lines including leukaemia, non-small cell lung cancer, melanoma, prostate cancer and breast cancer cell lines. Compound 6e even exhibited lethal effect (above 100% inhibition) against several leukaemia, melanoma, renal cancer cell lines. Interestingly, it showed highly potent



Scheme 1. (a) Reagents and conditions: (i) dioxane, rt, 1 h. (b) Reagents and conditions: (i) NH₂NH₂ 99%, propanol, 2 h (ii) POCl₃, reflux 70 °C, 2 h (iii) *p*-phenylenediamine, butanol, 110 °C, 1 h, (iv) benzoyl chlorides, acetonitile, triethylamine, 6 h (v) arylisocyanates, DMF, reflux, 8 h, (vi) 1a–c, Cs₂CO₃, acetonitrile, reflux, 6 h, (vii) piperazines, K₂CO₃, KI, ethanol, reflux, 3 h.

inhibitory or lethal effects against most of the tested leukaemia and melanoma cell lines.

Furthermore, their analogue (7b) linked to the phthalazine nucleus via an ether linkage also showed excellent broad

spectrum inhibitory or lethal activity against most of the tested NCI cell lines representing all the nine tumour subpanels specially those of leukaemia, colon, melanoma and breast cancer cell lines, with mean growth inhibition of 106.99%. However, its analogue



Scheme 2. Reagents and conditions: (i) NH₂NH₂ acetic, reflux, 3 h (ii) POCl₃, reflux 110 °C, 1 h (iii) *p*-phenylenediamine, butanol, 110 °C, 1 h, (iv) phenylisocyanates, DMF, reflux, 8–10 h, (v) **1a–c**, Cs₂CO₃, acetonitrile, reflux, 6–8 h.



Scheme 3. Reagents and conditions: (i) aniline derivatives, butanol, K₂CO₃, KI, reflux, 3 h (ii) NBS, dibenzoyl chloride, reflux, 24 h (iii) aniline derivatives, acetone, K₂CO₃, KI, reflux, 6 h (iv) phenol derivatives, NaH, acetone, reflux, 8 h.

(7e) having a methyl substituent at 4-position of phthalazine core only showed moderate cell growth inhibition against leukaemia and breast cell lines (Table S3 in Supplementary material).

Thus, the unsubstituted biarylurea derivative **(13a)** displayed broad spectrum cell growth inhibition above 90% against various cell lines including non-small cell lung cancer, melanoma, CNS

cancer, melanoma and breast cancer cell lines. Interestingly, its disubstituted analogue (**13c**) exhibited an excellent broad spectrum lethal activity against most of the tested NCI cell lines representing all the nine tumour subpanels specially those of non-small lung cancer, colon, CNS and melanoma cell lines, with mean growth inhibition of 145.09%. Surprisingly, the 4-chloro

substituted derivative (**13b**) did not show any significant cell line growth inhibition (Table S3 in Supplementary material).

For the vatalanib analogues having a 4-anilino (16a, and 16d) or 4-phenoxy substituent (17a) linked to the phthalazine via methylene spacer; It was found that all the three tested derivatives displayed remarkable broad spectrum cell growth inhibition above 90% against various cell lines including leukaemia, melanoma and breast cancer cell lines, with the meta methoxy analogue (16d) showing the most prominent inhibition against most of the tested cell lines with mean growth inhibition of 116.00%.

Neither of the biarylamides (**5b**, **and 5d**) nor the piperazines (**8a**, **8d**, **8f**, **8g**, **8h and 8i**) showed any significant cell line growth inhibition under the same test conditions (Table S3 in Supplementary material).

4.1.1.2. In vitro 5 log dose full NCI 60 cell panel assay. Eight compounds (**6b**, **6e**, **7b**, **13a**, **13c**, **16a**, **16d and 17a**) were selected by NCI for further 5 log dose screening against full NCI 60 cell panel. All the 60 cell lines, representing nine tumour subpanels (leukaemia, non-small cell lung cancer, colon cancer, CNS cancer, prostate cancer, melanoma, ovarian cancer, renal cancer and breast cancer) which were incubated at five different concentrations (0.01, 0.1, 1, 10 and 100 μ M) of each of the test compounds. The outcomes were used to create log concentration vs % growth inhibition curves, then three response parameters (GI₅₀, TGI and LC₅₀) were calculated for each cell line, (Tables S4 and S5 in Supplementary material).

All investigated biarylureas (**6b**, **6e**, **7b**, **13a**, **and 13c**) and vatalanib analogues (**16a**, **16d**, **and 17a**) revealed potent antiproliferative activity against most of the tested cell lines representing the nine different subpanels with GI_{50} values between 0.15–8.41 μ M, except for **16a** which was insensitive to prostate and MCF-7 breast cancer cell lines.

With regard to the sensitivity against the tested cell lines, compound (**7b and 13c**) exhibited the highest broad spectrum submicromolar inhibitory activity against most of the tested cell lines specially those of leukaemia, colon, melanoma, breast cancer and renal (**13c only**) cell panels with Gl₅₀ values of 0.15–2.81 μ M and 0.2–2.66 μ M for **7b and 13c**, respectively. It is worth noting that **13c** showed submicromolar Gl₅₀s against all tested leukaemia and melanoma cell lines.

As for the selectivity of the test compounds towards some specific tumour subpanels, which is calculated based on the ratio obtained by dividing the full panel MID (the average sensitivity of all cell lines towards the test agent) by their individual subpanel MID (the average sensitivity of all cell lines of a particular subpanel towards the test agent)^{24,25}. As per this criterion, the test compounds were regarded to be more selective against leukaemia, renal, melanoma, colon and breast cancer subpanels.

4.1.2. In vitro cytotoxic activity against MCF-7, HCT-116 and HepG-2 cancer cell lines

The growth inhibition of the rest of synthesised compounds (not selected by NCI) (**5a, 5c, 6a, 6c, 6d, 6f, 7c, 7d, 7f, 8b, 8c, 8e and 8j**) was also evaluated against two specific cell lines, namely MCF-7 and HCT-116 using doxorubicin as a reference drug. In addition, compounds (**12a, 12b, 12c, 16b, 16c and 17b**) were evaluated against a third cell line (HepG-2) These first two cell lines were selected based on the sensitivity of the previously NCI-tested derivatives towards them amongst the 60 NCI panel. The growth inhibition is expressed as the median growth inhibitory concentration (IC₅₀) which corresponds to the concentration

required for 50% inhibition of cell viability and are provided in (Table S6 in supplementary material).

Investigation of the results of the growth inhibition of the tested molecules revealed that the biarylurea-based phthalazines (series B and C) generally exhibited moderate to significant cyto-toxicity on both cell lines. This was relatively in accordance with the NCI findings for the same series of compounds.

Further analysis of the inhibitory results within the biarylureabased derivatives linked to phthalazine core via an NH-linker (series B) revealed that, the 4-chloro-3-trifluoromethyl derivatives (6c and 6f), bearing an electron withdrawing substitution pattern similar to that of sorafenib, displayed enhanced growth inhibition on both cell lines compared to their unsubstituted analogues (6a and 6d) (IC₅₀s = 6.2, 6.0 and 3.2, 3.1 μ M compared to 67.6, 91.2 and 67.6 and 57.5 μ M respectively).

As for the biarylureas bearing an ether linker (**series 7**), the 4chloro-3-trifluoromethyl derivative (**7c**) similarly displayed significant inhibiton on both cell lines, ($IC_{50}s = 2.5$ and $2.6 \mu M$). Surprisingly, its methyl analogue (**7f**) demonstrated weaker activity ($IC_{50}s = 31$ and $49 \mu M$) compared to its unsubstituted analogue (**7d**, $IC_{50}s = 7.8$ and $7.2 \mu M$). However, the amide-based derivatives (**series A**) and the piperazine-based derivatives have not shown any interesting cell line inhibition which was also consistent our previous results.

Unfortunately, neither the 4-chlorophthalazines (**12a-c**) nor the vatalanib analogues (**series D and E**) showed any significant cell line inhibition (Table S6 in Supplementary Material).

4.1.3. In vitro VEGFR-2 tyrosine kinase activity

4.1.3.1 VEGFR-2 kinase activity at single-dose 10 μ M concentration. The VEGFR-2 tyrosine kinase assay was performed in an attempt to investigate the mechanism of potent antiproliferative activity exerted by the synthesised compounds. The VEGFR tyrosine kinase assays were performed at BPS Bioscience (www. bpsbioscience.com). All the synthesised compounds representing the six series were evaluated for their ability to inhibit VEGFR-2 tyrosine kinase at single dose of 10 μ M.

Investigation of the results of VEGFR-2 inhibitory activities among the synthesised phthalazines revealed that: Within the biaryl ureas (series B, C): derivatives having a 4-chloro-3-trifluoromethyl substitution pattern on the terminal phenyl ring similar to that of sorafenib (6c, 6f, 7c, 12c and 13c) tended to exhibit enhanced VEGFR-2 inhibitory activity as excepted from cell line results compared to their monosubstituted or unsubstituted analogues.

In accordance with cell lines results, among these biaryl ureas, the introduction of a 4-chloro group to the phthalazine core replacing the 4-CH₃ or unsubstituted derivatives, resulted in favourable increase in VEGFR-2 inhibitory activity (12a-c, 13a-c compared to **6a-f**, **7a-f**), which might be attributed to enhanced lipophilicity of the chloro group. Thus, compounds **6c**, **12b**, **12c** and **13c** showed 70–100% inhibition at 10 μ M concentration (Table 1).

However, the vatalanib analogues (16a–d and 17a,b) (series **D**, **E**), they generally exhibited weak to moderate activity, with the derivatives having unsubstituted anilino or phenoxy moiety (16a, 17a) showing relatively better activity than their meta substituted analogues (Table 2).

As expected from the cell lines results, neither of the amidebased derivatives (**5a–d**) (series **A**) nor the piperazines (**8a–j**) (series **F**) showed any significant VEGFR-2 inhibition in accordance with cell lines results.



5a-d.	Series	A)	
ou u,	001100		

(7a-f, 13a-c, Series C)

Cpd No	Х	R	<i>R</i> ₁	R ₂	% inhibition
5a	-	Н	Н	-	4
5b	-	Н	Cl	-	8
5c	-	CH₃	Н	-	12
5d	-	CH₃	Cl	-	15
ба	NH	Н	Н	Н	13
6b	NH	Н	Cl	Н	20
бс	NH	Н	Cl	CF ₃	70
6d	NH	CH_3	Н	Н	15
бе	NH	CH ₃	Cl	Н	19
6f	NH	CH ₃	Cl	CF3	32
12a	NH	CL	Н	Н	26
12b	NH	Cl	Cl	Н	70
12c	NH	Cl	Cl	CF3	78
7a	0	Н	Н	Н	5
7b	0	Н	Cl	Н	13
7c	0	Н	Cl	CF3	47
7d	0	CH3	Н	Н	10
7e	0	CH ₃	Cl	Н	14
7f	0	CH ₃	Cl	CF3	21
13a	0	CL	Н	Н	24
13b	0	Cl	Cl	Н	38
13c	0	Cl	Cl	CF ₃	100
Staurosporin				2	100

The bold values are the most active compounds.

Table 2. The VEGFR-2 inhibition per cent of the synthesised phthalazines (series D, E, F) at $10 \,\mu M$ concentration. CI



(16a-d, Series D) (17a,b, Series E)

Cpd No

16a 16b

16c

16d

17a

17b

8a

8b

8c

8d

8e

8f

8g



Ŕ

% inhibition

47

21

19

24

31

15 13

8 9

5

9

14

13

9

6

10

100

• • •			
Y	Х	R	<i>R</i> ₁
NH	Н	-	-
NH	Cl	-	-
NH	CH₃	-	-
NH	OCH ₃	-	-
0	Н	-	-
0	CH₃	-	-
-	-	Н	ethoxycarbonyl
-	-	Н	phenyl
-	-	Н	2-fluorophenyl
-	-	н	pvridvl

н

 CH_3

 CH_3

2-furoyl

phenyl

ethoxycarbonyl

8h _ CH_3 2-fluorophenyl pyridyl 8i CH_3 8i CH_3 2-furoyl Staurosporin

The bold values are the most active compounds.

Table 3.	The IC ₅₀	values	for	compounds	(6c ,
12 b, 12c	, 1 3c).				

Compound ID	VEGFR-2 IC ₅₀
6с	13.4 μM
12b	4.4 μM
12c	2.7 μM
13c	2.5 μM

4.1.3.2. Measurement of potential VEGFR-2 inhibitory activity (IC₅₀). Further investigation for the promising candidates, (6c, 12b, 12c, 13c), which exhibited VEGFR-2 inhibition percent above 70% at 10 µM concentration, were evaluated at five different concentrations (0.01, 0.1, 1, 10 and 100 μ M) to calculate their IC₅₀ values (Table 3 and Figure 3).

Results confirmed the significant inhibition of 4-chlorophthalazines bearing a biarylurea tail with a terminal 4-chloro substitution (12b) or a terminal 4-chloro-3-CF $_3$ substitution (12c, 13c) with $IC_{50}s$ of 4.4, 2.7 and 2.5 μM respectively.

4.1.4. In vitro HUVEC anti-proliferative assay

In order to further assess the antiangiogenic activity of the promising candidates, three compounds (12b, 12c and 13c) showing best VEGFR-2 IC₅₀s were selected to be tested for their ability to in vitro inhibit VEGF-induced HUVEC cell line proliferation at single dose of 10 µM concentration.



Figure 3. IC₅₀ curves for compounds (6c, 12b, 12c and 13c) against the VEGFR-2 kinase.

Table 4. The effect of Compounds (12 b, 12c, 13c) on HUVEC proliferation.

Compound ID	% Cell growth	% Cell inhibition
12b	20.17	79.83
12c	27.42	72.58
13c	28.40	71.60

The HUVEC anti-proliferative assay was also carried out in BPS Bioscience Corporation, San Diego, CA, USA (www.bpsbioscience.com).

Angiogenesis process comprises endothelial cell (EC) outgrowth from the parent vessel, followed by proliferation, migration, tube formation, alignment, and anastomosis to other vessels. Several *in vitro* models have attempted to recreate this complex progression of events²². The development of atherosclerotic plaques and angiogenesis, the role of the endothelium in the response of the blood vessel wall to shear forces and stretch in addition to creating a model system for the study of the regulation of endothelial cell function had emphasised the importance of using human umbilical vein endothelial cells (HUVECs). As most endothelial cell assays utilise human umbilical vein endothelial cells (HUVECs) or bovine aortic endothelial cells (BAECs) as being relatively easy to harvest from large blood vessels and also as representatives of vascular endothelial cells *in vivo*²³.

The test compounds **(12b, 12c and 13c)** manifested significant inhibition of HUVEC cell lines of 79.83%, 72.58% and 71.60%, respectively, which may support their potential antiangiogenic activity (Table 4 and Figure 4).



Figure 4. The bar graphs showing the HUVECs growth percentage after treatment with the target compounds.

4.1.5. Cell-cycle analysis

In an attempt to elucidate the potential mechanism of action of the synthesised phthalazines that exhibited potent anti-proliferative activity against the NCI cell panel but weak or moderate VEGFR-2 inhibitory activity, compounds **(7b and 16a)** were selected to investigate their effect on cell-cycle progression, and induction of apoptosis using breast cancer adenocarcinoma cell line (MCF-7) and colon cancer cell line (HCT-116), respectively.



Figure 5. Effect of compound 7b on DNA-ploidy flow cytometric analysis of MCF7 cells. MCF-7cells were treated with DMSO 0.01% or compound 7b at its GI_{50} (0.32 μ M), for 24 h and 48 h, and the harvested cells were subjected to Cell-cycle analysis using a FACS Calibur flow cytometer (A,B and C). Bar chart shows percentage of MCF7 cells at each phase of cell cycle in DMSO and compound 7b treated cells.

From another point of view, since the inhibition of VEGF pathway has a greater effect on the induction of endothelial cell apoptosis and the decrease of vascular tubulogenesis, as the repair of endothelial lining defects caused by endothelial apoptosis is coordinated by growth factors, mainly by vascular endothelial growth factor (VEGF), which conveys survival signals to endothelial cells and acts as a potent antiapoptotic, proliferation stimulating factor²⁶; thus, the biarylurea derivative (**13c**) (VEGFR-2 IC₅₀ = 2.5 μ M) was selected to test its effect on cell cycle analysis and induction of apoptosis using breast cancer adenocarcinoma cell line (MCF-7).

Cell cycle is a chain of events that takes place in a cell leading to its division and replication. G1 phase, S phase (synthesis), G2 phase (collectively known as interphase) and M phase (mitosis) are considered as the four main distinct phases of the cell cycle. The G1-phase, also called post-mitotic pre-synthesis phase, directly follows cell division. The S- or synthesis phase is characterised by the process of DNA replication. The G2-, premitotic or post-synthetic phase is the time when the cell prepares to split off in two cells, the actual division. Finally, in the M- or mitosis-phase division, the doubled DNA organised in chromosomes is separated²⁷.

The effect of compound (**7b and 13c**) on the normal cell-cycle progression was characterised using flow cytometric analysis of the DNA ploidy in MCF-7 cells using BD FACSDIVA TM software. Exposure of MCF-7 cells to either **7b or 13c** at their **Gl**₅₀ concentration (0.32 μ M, 0.57 μ M, respectively) for 24 h and 48 h was shown to induce a remarkable disruption in cell cycle profile and cell-cycle arrest at S-phase boundary with concurrent

time-dependent increase in pre-G cell population (Figures 5 and 6). **13c** showed excellent disruption and even more prominent increase in sub-G1 cell population than **7b**. The observed increase in sub-G1 cell population may imply DNA fragmentation and apoptosis as a potential mechanism for **7b/13c**-induced cancer cell death.

Furthermore, exposure of HCT-116 cells to **16a** at GI₅₀ concentration (1.20 μ M) for 24 h and 48 h also seemed to induce a significant action at both S phase and sub-G1 cell population (Figure 7).

4.1.6. Apoptosis determination

To further investigate the ability of compounds (7b, 13c and 16a) to induce apoptosis, an Annexin V (conjugated to FITC) apoptosis detection kit was employed. This assay detects phosphatidylserine (PS) expressed on the surface of apoptotic cells and fluoresces green after interacting with the labelled Annexin V. During early apoptosis, membrane asymmetry is lost, and PS translocates from the cytoplasmic side of the membrane to the external leaflet. Propidium iodide (PI), the counter stain used in this assay, has the ability to cross only compromised membranes to intercalate into the DNA. Therefore, PI is used to detect the late stages of apoptosis by the presence of red fluorescence. Exposure of MCF-7 cells to **7b** at its GI_{50} (0.32 μ M) for 24 h and 48 h increased the percentage of Annexin-V positive cells indicating an early (lower right quadrant) or late (upper right quadrant) apoptosis in a timedependent manner compared to DMSO treated cells (Figure 8). However, 13c and 16a increased the percentage of Annexin-V



Figure 6. Effect of compound 13c on DNA-ploidy flow cytometric analysis of MCF7 cells. MCF-7cells were treated with DMSO 0.01% or compound 13c at its GI_{50} (0.57 μ M), for 24 h and 48 h, and the harvested cells were subjected to cell-cycle analysis using a FACS Calibur flow cytometer (A, B and C). Bar chart shows percentage of MCF7 cells at each phase of cell cycle in DMSO and compound 13c treated cells.

positive cells in lower right quadrant indicating early apoptosis (Figures 9 and 10).

4.1.7. Effects of 7b on the cellular and nuclear morphology

To further examine the apoptosis inducing effect of **7b**, the cellular as well as nuclear morphological changes for MCF-7 cells treated with **7b** (0.32 µM) were studied following Dapi staining. The effect of 7b on cell morphology was initially analysed with light microscopy. While control cells treated with DMSO exhibited normal morphological features, cells treated with 7b for 24 and 48 h showed deteriorated morphological changes including cell rounding, detachment and cellular fragmentation (Figure 11(A)). Similarly, fluorescence staining further indicated that, while DMSOtreated control cells exhibited uniformly dispersed chromatin, 7btreated cells showed typical apoptotic characteristics; including condensation of chromatin (brightly stained cells), blubbing with the appearance of nuclear fragmentation (arrow heads indicate apoptotic nucleus) (Figure 11(B)). These results collectively confirms the ability of compound (7b) to induce cellular apoptosis in MCF-7 cells as a mechanism of cancer cell death.

4.1.8. Effect of compound 7b treatment on the expression level of cleaved caspase-3

Caspase-3 is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases is considered as one of the important keys in cellular apoptosis process. Actually, caspases exists as inactive proenzymes that changed to the active form by undergoing proteolytic processing. Cleaved caspase-3 further activates a cascade of caspases that induce cell death. Thus, the ability of compound **7b** to increase the expression of cleaved caspase-3 was studied as a driving force in **7b**-induced apoptotic cell death. Exposure of MCF-7 cells to compound (**7b**) (0.32 μ M) for 24 h and 48 h resulted in time-dependent increase in cleaved caspase-3 protein expression, indicating a pivotal involvement of caspases in the induced cancer cell death (Figure 12).

4.2. Molecular modelling studies

Molecular docking study was performed using AutoDock Vina²⁸ through docking of the synthesised compounds in the VEGFR-2 kinase active site. Docking study aimed to interpret the VEGFR-2 inhibitory activity of the investigated molecules and gain further insight into their relative binding affinities and binding interactions with the kinase active site. The coordinates of the VEGFR-2 structure were obtained from the crystal structure of VEGFR complexed with sorafenib as its inhibitor (PDB code 4ASD), which revealed the hydrogen bond interactions between the NH and CO motifs of urea moiety with the backbone of Asp1046 and the carboxylic acid moiety of Glu885, respectively, as well as a H-bond with Cys919 residue in the hinge region of the kinase active site²⁰.

Owing to the fact that the chloro group of the co-crystallised ligand (sorafenib) is in the far proximity to any halogen-bond²⁹⁻³¹ acceptor in the binding site (Figure S7 in Supplementary material),



Figure 7. Effect of compound 16a on DNA-ploidy flow cytometric analysis of HCT-116 cells. HCT-116 cells were treated with DMSO 0.01% or compound 16a at its GI_{50} (1.20 μ M), for 24 h and 48 h, and the harvested cells were subjected to Cell-cycle analysis using a FACS Calibur flow cytometer (A,B and C). Bar chart shows percentage of HCT-116 cells at each phase of cell cycle in DMSO and compound 16a treated cells.



Figure 8. Effect of compound 7b treatment on induction of apoptosis. MCF-7 cells were treated with DMSO 0.01% or compound 7b at its Gl_{s0} (0.32 µM) for 24 or 48h, the harvested cells were stained with Annexin V-FITC apoptosis detection kit and Analyzed on a Flow cytometer.

we excluded investigating halogen-bond contacts in our dockingbased assessment.

The best-scored pose of the biarylurea derivative (**6c**) reproduced the key interactions of the co-crystallised ligand (sorafenib) which includes H-bonding interactions of Glu885 and Asp1046 with the urea group of **6c**. In addition, other hydrophobic interactions can be observed for the hydrophobic side chains of Ile892, Leu1019 and Val898 with the halogen groups (chloro and trifluoromethyl) of the phenyl moiety of **6c**. Nevertheless, losing the H-bonding interaction of the Cys 919 with the terminal amide group of sorafenib can explain the lower activity of **6c** compared to sorafenib (Figure 13(A)). The relative higher inhibitory activity of **6c** compared to similar analogues of **6a** and **6b** is most probably attributable to the fact that **6c** possessing additional halogen group (trifluoromethyl group) on the phenyl moiety which contributes to an additional hydrophobic interaction, this also agrees with the predicted score of the best poses by AutoDock Vina²⁸ (Table 5). More information about rationalising the docking poses of the **6d, 6e and 6f** can be found in (Figure S8 in Supplementary material).

Unlike **6c**, the predicted best scored poses of both biarylurea derivatives **12b** and **12c** showed a flip of 180 degrees compared to sorafenib and biarylurea compound (**6c**) (Figure 13(B)). This implies that the chlorophthalazine moiety of both derivatives **12b**



Figure 9. Effect of compound 13c treatment on induction of apoptosis. MCF-7 cells were treated with DMSO 0.01% or compound 13c at its Gl₅₀ (0.57 µM) for 24 or 48h, the harvested cells were stained with Annexin V-FITC apoptosis detection kit and Analyzed on a Flow cytometer.



Figure 10. Effect of compound 16a treatment on induction of apoptosis. HCT-116 cells were treated with DMSO 0.01% or compound 16a at its Gl₅₀ (1.20 µM) for 24 or 48h, the harvested cells were stained with Annexin V-FITC apoptosis detection kit and Analyzed on a Flow cytometer.

and **12c** is directed towards the 4-chloro-3-trifluoromethylphenyl moiety of sorafenib. Avoiding a possible clash of the chloro group with the backbone of Cys 919 can explain this flipping behaviour (Figure S9 in Supplementary material). The flipped pose showed interaction pattern in the binding site that maintained the Hbonding interaction of Glu885, however, in this case with the amino group of 12b and 12c. Also, chlorophthalazine ring was packed in the hydrophobic region of Ile892, Val898 and Leu1019. Similarly, the chlorophenyl moiety of 12b and the 4-chloro-3-trifluoromethylphenyl moiety of 12c showed hydrophobic contacts with the side chains of Phe918 and Leu840 (Figure 13(B,D)). Owing to the existence of additional hydrophobic contacts of 12c (extra halogens) compared to 12a and 12b, the predicted scores showed relative improvement (Table 5). This also agrees with the marginal improvement of the observed inhibitory activity of 12c compared to similar analogs. Additional Figures of the docked poses of 12a, 12b and 12c can be found in the (Figure S10 in Supplementary material).

Like **12c**, the predicted pose of **13c** showed the same flip and relatively the same interaction pattern. Only exception is that the isosteric ether link in **13c** showed H-bonding interaction with Asp1046 instead of Glu885 with **12c** as shown in (Figure 13(C)). This agrees with the biological activity observed for both **12c** and **13c**.

5. Conclusion

Four series of phthalazine-based derivatives bearing biarylamides (5a-d), biarylurea (6a-f, 7a-f, 12a-c and 13a-c) or a substituted piperazine moiety at position 1 of the phathalazine nucleus (8a-j), in addition to two other series of vatalanib analogs (16a-d, and 17a,b) were designed, synthesised as anticancer agents exerting potent anti-proliferative activity as well as apoptosis inducers in tumour cells. Eight of the phthalazines derivatives; namely the biarylureas (6b, 6e, 7b, 13a and 13c) and the vatalanib analogues (16a, 16d and 17a) exhibited excellent broad spectrum anti-proliferative activity in NCI 5-log dose screening against 60 cell panel with GI₅₀ values ranging from 0.15 to 8.41 µM, especially on leukaemia, renal, melanoma and breast cancer cell lines. Accordingly, the three compounds (7b, 13c and **16a)** were selected to further investigate the potential underlying mechanisms that induced cancer cell death. The latter three compounds were found to induce cell-cycle arrest with concurrent increase in pre-G cell population and increase the apoptotic cell population in time-dependent manner. Moreover, compound (7b) was found to disrupt the normal cellular and nuclear morphology and increase the expression of cleaved caspase-3, the pro-apoptotic protein, in MCF-7 cell lines which collectively indicate the involvement of these compounds in apoptotic-induced cell death. Moreover, all the synthesised phthalazines were evaluated for



Figure 11. Effect of compound 7b on the cellular and nuclear morphology. MCF-7 cells were seeded on cover slips in a 6- well tissue culture plate, the cells then were treated with DMSO 0.01% or compound 7b (0.32μ M) for 24 or 48h, the cells were imaged with the light microscope to examine the cellular morphology (A) or stained with the nuclear stain Dapi to study the nuclear morphology using fluorescence microscope (B).



Figure 12. Effect of compound 7 b on cleaved caspase-3 protein expression. MCF-7 cells were seeded on cover slips in a 6-well tissue culture plate, the cells then were treated with DMSO 0.01% or compound 7b at its $GI_{50}(0.32 \mu M)$ for 48h, the cells were then permiabilised, fixed, blocked and stained with the primary and secondary antibodies, the nuclear stain Dapi was used as a counter stain. The image were taken using a fluorescence microscope.

their VEGFR-2 inhibitory activity, which revealed the significant inhibition of the 4-chlorophthalazines having a biarylurea tail with either a terminal 4-chloro (**12b**) or a terminal 4-chloro-3-trifhuoromethyl substituents (**12c and 13c**) with IC₅₀ of 4.4, 2.7 and 2.5 μ M, respectively. 4-chlorophtalazines were found to exhibit better VEGFR-2 activity than their corresponding 4-methyl or 4-unsubstituted analogues. **12b, 12c and 13c** also displayed

significant inhibition of VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) with 79.83, 72.58 and 71.6% inhibition, respectively, at $10\,\mu$ M concentration. Finally, molecular docking study of the active biarylurea compounds (6c, 12b, 12c and 13c) in VEGFR-2 kinase active site revealed their ability to form the essential H bond interactions with Glu 885 or Asp1046 key residues in the VEGFR-2 active site.



Figure 13. Overlay of the best-scored docking poses of some relevant compounds on the co-crystallised ligand Sorafenib (cyan sticks) in the binding site of VEGFR2 (PDB: 4ASD):. (A) The docking pose of **6c** as magenta sticks, (B) the docking poses of **12b** and **12c** as yellow and purple sticks, respectively, and (C) the docking pose of **13c** as gold sticks. (D) The docking poses of **12c** and **13c** at a different perspective of the binding site showing the extended hydrophobic contact of the chloro and trifluoromethyl phenyl moiety with the side chains of PHE-918 and LEU-840. The yellow dashed-lines represent the polar contacts (H-bonding interactions). Non-polar hydrogen atoms were omitted for clarity. All presented docking poses are the best-scored by AutoDock Vina.²⁸

Table 5. The score of best-scored poses of some relevant compounds. The score is expressed as a binding affinity (kcal/mol) as an output of AutoDock Vina.^a

Compound Number	Score (SD)	Average Number of Poses Per Run
ба	-11.4 (0)	4.6
6b	—11.5 (0)	4.6
бс	-12.4 (0.06)	5.3
12a	-11.0 (0)	4.3
12b	-11.1 (0.06)	5
12c	—11.5 (0)	8.3
13a	—10.7 (0)	9
13b	-10.8 (0)	9
13c	-11.0 (0)	9

^aThe shown score is the mean of three consecutive runs. The docking method was validated by successful pose-retrieval docking experiment of Sorafenib (score: -12.3(0)). SD is the standard deviation.

6. Experimental

6.1. Chemistry

Starting materials and reagents were purchased from Sigma – Aldrich or Acros Organics. Melting points were recorded on Gallen Kamp apparatus and were uncorrected. FT-IR spectra were recorded on a Shimadzu IR 435 spectrophotometer. ¹HNMR spectra were recorded in δ scale given in ppm on a Varian 400 MHz spectrophotometer or a Varian 300 MHz spectrophotometer.

Coupling patterns are described as follows: *s*, singlet; *d*, doublet, *dd*, doubled doublet; t, triplet; m, multiplet. *J* describes a coupling constant. The coupling constants were rounded off to one decimal place. MS spectra mass were recorded on Hewlett Packard 5988 spectrometer (70 eV). Elemental analyses were performed at the Microanalytical Center, Al-Azhar University. Compounds $1a-c^{21}$, $2a,b^{32}$ and $3a,b^{33}$, 9 and 10^{34} were prepared following reported procedures.

6.1.1. Synthesis of N^1 -(4-substituted-phthalazin-1-yl)benzene-1,4diamine (4a,b)

General procedure:

p-Phenylenediamine (0.33 g, 3.12 mmol, 3equiv) and the respective chlorophthalazine (2.08 mmol, 2equiv) were treated with 2-BuOH (7.5 ml) in a tube and heated to 110 °C. The reaction quickly became a solid, yellow mass. After four hours, the reaction was cooled and diluted with water. The resultant slurry was then partitioned between equal volumes of DCM and 1 N NaOH (15 ml). The aqueous layer was extracted into DCM (2x15 ml). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The resulting orange solid was crystallised from (EtOAc/pet ether 1:1) to afford the title compounds **(4a,b)** as an orange crystals.

6.1.1. N^{1} -(*Phthalazin-1-yl*)*benzene-1,4-diamine* (4*a*). Yield (0.21 g, 91%); mp 284–286 °C; ¹HNMR (300 MHz, DMSO-d₆): δ 9.15 (1H, *s*, -NH D₂O exchangeable), 9.04 (2H, *s*, -NH₂ D₂O exchangeable), δ 8.95–8.92 (2H, d, J=9 Hz, phthalazine), δ 8.18–8.15 (2H,d, J=9 Hz, phthalazine), δ 7.65–7.62 (2H,d, J=9 Hz, ArH), δ 6.97–6.83 (2H,d, J=9 Hz, ArH); FT-IR (i max, cm⁻¹): 3400 (NH₂), 3329 (NH); **MS** (Mwt.: 236.11): *m/z* 236.00 (M+, 43.00%), 212.00 (100.00%), 118.00 (54.00%), 56.00 (70.00%); Anal. Calcd for C₁₄H₁₂N₄: C, 71.17; H, 5.12; N, 23.71; Found: C, 71.34; H, 5.17; N, 23.96

6.1.1.2. N¹-(4-Methylphthalazin-1-yl)benzene-1,4-diamine (4b). Yield (0.22 g, 88%); mp 240–242 °C; ¹HNMR (300 MHz, DMSO-d₆): δ 8.88 (1H, *s*, -NH D₂O exchangeable), 8.85 (2H, *s*, -NH₂ D₂O exchangeable), δ 8.13–8.08 (2H, d, J=7Hz, phthalazine), δ 7.95–7.92 (2H, d, J=7Hz, phthalazine), δ 7.46–7.43 (2H, d, J=9Hz, ArH), δ 6.83–6.76 (2H, d, J=9Hz, ArH), δ 2.78 (3H, *s*, CH₃); ¹³CNMR (100 MHz, DMSO): δ 162.4, 150.5, 135.2, 134.5, 131.2, 130.7, 128.0, 127.3, 125.0, 122.8, 120.7, 120.2, 115.6, 115.3, 18.2; FT-IR (ú max, cm⁻¹): 3385 (NH₂), 3321 (NH); MS (Mwt.: 250.12): *m*/ *z* 250.00 (M+, 50.00%), 249.00 (100.00%), 108.00 (60.92%), 65.00 (77.59%); Anal. Calcd for C₁₅H₁₄N₄: C, 71.98; H, 5.64; N, 22.38; Found: C, 72.09; H, 5.78; N, 22.52.

6.1.2. Synthesis of N-(4-(4-Substitutedphthalazin-1-ylamino)phenyl)-4-substituted-benzamides (5a-d)

General procedure:

To a stirred solution of the respective N1-(4-arylphthalazin-1-yl)benzene-1,4-diamine **(4a,b)** (10.0 mmol, 1equiv) and triethylamine (1.1 ml, 10.0 mmol) in acetonitrile (20 ml), the respective benzoyl chloride (viz.; benzoyl chloride, 4-chlorobenzoyl chloride) (10.0 mmol, 1equiv) was added and the mixture was heated under reflux for 6 h, until the disappearance of starting material as judged by TLC (CHCl₃/CH₃OH 9.5:0.5). The reaction mixture was filtered and then the filtrate was concentrated *in vacuo*, to afford the crude product which was purified by flash column chromatography (EtOAc/pet ether 9:1) to afford **5a–d** as yellow crystals.

6.1.2.1. *N*-(4-(*Phthalazin-1-ylamino*)*phenyl*)*benzamide* (5*a*). Yield (0.17 g; 50%), mp 142–144 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 9.66 (1H, *s*, –NH D₂O exchangeable), δ 9.12 (1H, *s*, –NH D₂O exchangeable), δ 8.62 (1H, *s*, J=8 Hz, phthalazine), δ 8.11–8.08 (2H, d, J=7.6 Hz, Ar-H), δ 7.98–7.96 (2H, d, J=8 Hz, phthalazine), δ 7.93–7.88 (2H, *m*, phthalazine), δ 7.64–7.62 (1H, *m*, Ar-H), δ 7.62–7.60 (2H, d, J=7.6 Hz, Ar-H), δ 7.59–7.57 (2H, d, J=6.8 Hz, Ar-H), δ 7.50–7.48 (2H, *m*, Ar-H); FT-IR (\acute{v} max, cm⁻¹): 3550, 3510 (2NH), 1649 (C=O); **MS** (Mwt.: 340.38): *m/z* 340.15 [M⁺, 1.58%), 138.05 (2.70%), 86.10 (100%); Anal. Calcd for C₂₁H₁₆N₄O: C, 74.10; H, 4.74; N, 16.46; Found: C, 74.34; H, 4.80; N, 16.58.

6.1.2.2. 4-Chloro-N-(4-(phthalazin-1-ylamino)phenyl)benzamide (5b). Yield (0.20 g; 54%), mp 156–158 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 10.50 (1H, s, –NH D₂O exchangeable), δ 9.15 (1H, s, –NH D₂O exchangeable), δ 8.99 (1H, s, phthalazine), δ 8.11–8.08 (2H, d, J = 9 Hz, Ar-H), δ 7.94–7.92 (2H,d, J = 7.6 Hz, phthalazine), δ 7.91–7.90 (2H, d, J = 7.6 Hz phthalazine), δ 7.56–7.54 (2H,d, J = 9 Hz, Ar-H), δ 7.53–7.51 (2H,d, J = 7.5 Hz, Ar-H), δ 7.31–7.28 (2H, m, Ar-H); FT-IR (ψ max, cm⁻¹): 3355, 3310 (2NH), 1640 (C=O); MS (Mwt.: 374.82): m/z 375.00 (M+, 1.57%), 245.00 (2.41%), 139.05 (46.44%), 111.10 (25.30), 64.00 (100.00%); Anal. Calcd for $C_{21}H_{15}CIN_4O;$ C, 67.29; H, 4.03; N, 14.95; Found: C, 67.52; H, 4.08; N, 15.22.

6.1.2.3. *N*-(4–(4-Methylphthalazin-1-ylamino)phenyl)benzamide(5c). Yield (0.24 g; 68%), mp 283–285 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 10.50 (1H, *s*, –NH D₂O exchangeable), δ 10.40 (1H, *s*, –NH D₂O exchangeable), δ 8.27–8.24 (2H, d, *J* = 7.6 Hz, phthalazine), δ 8.02–8.00 (2H, m, Ar-H), δ 7.99–7.97 (2H,d, *J* = 7.6 Hz, phthalazine), δ 7.77–7.73 (1H, d, *J* = 9.2 Hz, Ar-H), δ 7.63–7.61 (2H,d, *J* = 7.2 Hz, Ar-H), δ 7.59–7.56 (2H,d, *J* = 7.6 Hz, Ar-H), δ 7.54–7.51 (2H, m, Ar-H), δ 2.91 (3H,s, CH₃); FT-IR (ú max, cm⁻¹): 3331, 3257 (2NH), 1649 (C=O); **MS** (Mwt.: 354.15): *m/z* 354.95 (M+, 1.18%), 315.95 (15.90%), 105.00 (100.00%); Anal. Calcd for C₂₂H₁₈N₄O: C, 74.56; H, 5.12; N, 15.81; Found: C, 74.78; H, 5.19; N, 16.04

6.1.2.4. 4-Chloro-N-(4-(4-methylphthalazin-1-ylamino)phenyl)benzamide (5d). Yield (0.20 g; 51%), mp 147–149 °C; ¹HNMR (**400 MHz, DMSO-d₆**): δ 10.65 (1H, *s*, –NH D₂O exchangeable), δ 10.45 (1H, *s*, –NH D₂O exchangeable), δ 8.05–8.03 (2H, d, J = 8 Hz, phthalazine), δ 7.97–7.95 (2H,d, J = 7.6 Hz, Ar-H), δ 7.88–7.86 (2H, d, J = 8 Hz, phthalazine), δ 7.63–7.61 (2H, d, J = 7.6 Hz, Ar-H), δ 7.59–7.57 (2H,d, J = 7.6 Hz, Ar-H), δ 7.31–7.28 (2H, *m*, Ar-H), δ 2.91 (3H, *s*,CH₃); ¹³CNMR (100 MHz, DMSO): δ 166.9, 165.0, 151.5, 138.45, 138.2, 137.5, 137.0, 136.9, 134.6, 133.9, 131.6, 130.9, 130.2, 130.2, 130.1, 129.2, 128.9, 128.1, 125.3, 121.5, 121.2, 18.9; FT-IR (\star max, cm⁻¹): 3300, 3192 (2NH), 1678 (C=O); MS (Mwt.: 388.85): *m/z* 388.90 (M+, 7.10%), 279.90 (7.84%), 248.95 (25.65%), 139.00 (100%); Anal. Calcd for C₂₂H₁₇ClN₄O: C, 67.95; H, 4.41; N, 14.41; Found: C, 68.24; H, 4.48; N, 14.49.

6.1.3. Synthesis of 1-Aryl-3-(4-(4-substitutedphthalazin-1-ylamino)-phenyl)ureas (6a-f)

General procedure:

To a stirred solution of the respective N1-(4-arylphthalazin-1yl)benzene-1,4-diamine **(4a,b)** (10.0 mmol, 1equiv) in DMF (20 ml), the respective phenylisocyanate (viz.; phenyl- isocyanate, 4-chlorophenylisocyanate, 3-trifluoromethyl-4-chlorophenylisocyanate) (10.0 mmol, 1 equiv) was added and the mixture was heated under reflux for 6 h, after which TLC (CHCl₃/CH₃OH 9:1) showed no starting material. The reaction mixture was poured over ice water, the formed precipitate was allowed to settle, then filtered off and dried to afford the crude products**(6a-f)** which was further crystallised from EtOAc.

6.1.3.1. 1-Phenyl-3–(4-(phthalazin-1-ylamino)phenyl)urea (6a). Yield (0.10 g; 30%), mp 145– 147 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 9.22 (1H, s,–NH D₂O exchangeable), δ 9.16 (1H,s, –NH D₂O exchangeable), δ 9.09 (1H, s, –NH D₂O exchangeable), δ 8.74 (1H, s, phthalazine), δ 8.68–8.66 (2H, d, *J*=8 Hz, phthalazine), δ 8.02–8.00 (2H, d, *J*=8 Hz, phthalazine), δ 7.58–7.56 (2H, m, Ar-H), δ 7.48–7.46 (2H, d, *J*=7.6 Hz, Ar-H), δ 7.31–7.29 (2H,d, *J*=7.2 Hz, Ar-H), δ 7.19–7.17 (1H, m, Ar-H), δ 6.98–6.96 (2H, d, *J*=7.2 Hz, Ar-H) FT-IR (\acute{v} max, cm⁻¹): 3300, 3047 (3NH), 1700 (C=O); **MS** (Mwt.: 355.14): *m/z* 355.10 (M+, 8.88%), 289.10 (9.51%), 123.10 (15.43%), 69.00(100.00%); Anal. Calcd for C₂₁H₁₇N₅O: C, 70.97; H, 4.82; N, 19.71; Found: C, 71.21; H, 4.89; N, 19.88

6.1.3.2. 1–(4-Chlorophenyl)-3–(4-(phthalazin-1-ylamino)phenyl)urea (6b). Yield (0.20 g; 53%), mp 168–171 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 10.33 (1H, s, –NH D₂O exchangeable), δ 10.07 (1H, s, –NH D₂O exchangeable), δ 9.16 (1H, s, –NH D₂O exchangeable), δ 8.96 (1H, s, phthalazine), δ 8.09–8.07 (2H, d, J=9.2 Hz, phthalazine), δ 7.63–7.61 (2H, d, J=9.2 Hz, phthalazine), δ 7.49–7.47 (2H, d, J=8.8 Hz, Ar-H), δ 7.44–7.42 (2H, d, J=8 Hz, Ar-H), δ 7.33–7.31 (d, J=8.8 Hz, 2H, Ar-H), δ 6.56–6.54 (2H,d, J=8 Hz, Ar-H); ¹³**CNMR** (100 MHz, DMSO): δ 160.2, 153.0, 145.4, 139.4, 137.6, 135.8, 134.8, 133.2, 132.6, 129.7, 129.2, 128.9, 127.7, 122.6, 122.4, 121.8, 121.5, 120.3, 119.9, 118.6, 115.6; FT-IR (\circ max, cm–¹): 3396, 3341 (3NH), 1672 (C=O); **MS** (Mwt.: 389.10): *m/z* 389.00 (M+, 1.51%), 281.95 (19.41%), 253.95(100.00%), 152.95 (13.00%); Anal. Calcd for C₂₁H₁₆ClN₅O: C, 64.70; H, 4.14; N, 17.96; Found: C, 64.89; H, 4.21; N, 18.17.

6.1.3.3. 1–(**4**-Chloro-3-(trifluoromethyl)phenyl)-3–(**4**-(phthalazin-1-ylamino)phenyl)urea (6c). Yield (0.22 g; 49%), mp 288–291 °C; **¹HNMR (400 MHz, DMSO-d₆)**: δ 10.08 (1H, *s*, –NH D₂O exchangeable), δ 9.36 (1H, *s*, –NH D₂O exchangeable), δ 9.11 (1H, *s*, –NH D₂O exchangeable), δ 8.22 (1H, *s*, Ar-H), 8.09–8.07 (2H, d, *J*=8.8 Hz, phthalazine), δ 7.97–7.95 (2H, d, *J*=8.8 Hz, phthalazine), δ 7.79 (1H, *s*, Ar-H), δ 7.69–7.67 (2H, d, *J*=9.6 Hz, Ar-H), δ 7.52–7.50 (2H, d, *J*=8.4 Hz, Ar-H), δ 7.39–7.37 (2H, d, *J*=8.4 Hz, Ar-H); FT-IR (\circ max, cm⁻¹): 3321, 3263, 3126 (3NH), 1649 (C=O); **MS** (Mwt.: 457.09): m/z 457.90 (M+, 1.06%), 415.90 (7.68%), 194.95(100.00%); Anal. Calcd for C₂₂H₁₅ClF₃N₅O: C, 57.71; H, 3.30; N, 15.30; Found: C, 57.93; H, 3.28; N, 15.48

6.1.3.4. 1–(**4**-(**4**-**Metyhlphthalazin-1**-ylamino)phenyl)3-phenylurea(6d). Yield (0.06 g; 20%), mp 284–286 °C; ¹**HNMR (300 MHz, DMSO-d_6)**: δ 9.20(1H, *s*, –NH D₂O exchangeable), δ 9.14 (1H, *s*, –NH D₂O exchangeable), δ 9.20 exchangeable), δ 9.06 (1H, *s*, –NH D₂O exchangeable), δ 8.93–8.91 (1H, d, J = 7 Hz, phthalazine), δ 8.77–8.75 (1H, d, J = 7 Hz, phthalazine), δ 8.22–8.20 (2H, d, J = 7 Hz, phthalazine), δ 7.85–7.83 (2H, d, J = 8.4 Hz, Ar-H), δ 7.52–7.49 (2H, d, J = 8.4 Hz, Ar-H), δ 7.43–7.40 (2H, d, J = 7.2 Hz, Ar-H), δ 7.25–7.23 (1H, m, Ar-H), δ 6.95–6.93 (2H, d, J = 7.2 Hz, Ar-H), δ 2.81 (3H, *s*, CH₃);) ; FT-IR (\circ max, cm⁻¹): 3292, 3194, 3132 (3NH), 1651 (C=O); **MS** (Mwt.: 369.16): *m/z* 369.00 (M+, 2.99%), 212.00 (6.90%), 93.00 (100.00%);Anal. Calcd for C₂₂H₁₉N₅O: C, 71.53; H, 5.18; N, 18.96; Found: C, 71.69; H, 5.27; N, 19.21

6.1.3.5. $1-(4-Chlorophenyl)-3-(4-(4-methylphthalazin-1-ylamino)-phenyl)urea (6e). Yield (0.20 g; 50%), mp 178–180 °C; ¹HNMR (400 MHz, DMSO-d_6): <math>\delta$ 9.20(1H, s, -NH D₂O exchangeable), δ 9.17 (1H, s, -NH D₂O exchangeable), δ 9.03 (1H, s, -NH D₂O exchangeable), δ 8.09–8.05 (2H, d, J=7.6 Hz, phthalazine), δ 8.09–8.05 (2H, d, J=7.6 Hz, phthalazine), δ 7.86–7.84 (2H, d, J=8.8 Hz, Ar-H), δ 7.73–7.71 (2H, d, J=8.8 Hz, Ar-H), δ 7.49–7.47 (2H, d, J=8.8 Hz, Ar-H), δ 7.33–7.30 (2H, d, J=8.8 Hz, Ar-H), δ 2.80 (3H, s,CH₃); FT-IR (\circ max, cm⁻¹): 3294, 3188, 3168 (3NH), 1681 (C=O); MS (Mwt.: 403.86): m/z 403.00 (M+, 1.51%), 276.95 (17.01%), 127.00 (100.00%); Anal. Calcd for C₂₂H₁₈ClN₅O: C, 65.43; H, 4.49; N, 17.34; Found: C, 65.62; H, 4.52; N, 17.52.

6.1.3.6. 1–(4-Chloro-3-(trifluoromethyl)phenyl)-3–(4-(4-methylphthalazin-1-ylamino)phenyl)-urea (6f). Yield (0.30 g; 63%), mp 258–260 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 9.43(1H, s, -NH D₂O exchangeable), δ 9.14 (1H, s, -NH D₂O exchangeable), δ 9.02 (1H, s, -NH D₂O exchangeable), δ 8.88–8.86 (2H, d, J=8 Hz, phthalazine), δ 8.24–8.22 (2H, d, J=8 Hz, phthalazine), δ 8.13 (1H, s,Ar-H), δ 7.97–7.95 (1H, d, J=9.2 Hz, Ar-H), δ 7.88–7.86 (1H, d, J=9.2 Hz, Ar-H), δ 7.63–7.61 (2H, d, J=10 Hz, Ar-H), δ 6.78–6.76 (2H, d, J=10 Hz, Ar-H), δ 2.80 (3H, s, CH₃); ¹³CNMR (100 MHz, DMSO): δ 160.8, 153.0, 140.7, 139.4, 134.0, 132.7, 131.9, 127.7, 127.3, 127.1, 125.6, 124.8, 123.9, 122.1, 121.8, 121.4, 119.8, 119.5, 118.8, 118.6, 117.6, 115.4, 19.6; FT-IR ($\acute{\upsilon}$ max, cm⁻¹): 3363, 3255, 3153 (3NH), 1681(C=O); **MS** (Mwt.: 471.86): *m/z* 472.10(M+, 0.30%), 223.00 (43.56%), 195.00 (70.63%), 52.05 (100%); Anal. Calcd for C₂₃H₁₇ClF₃N₅O: C, 58.54; H, 3.63; N, 14.84; Found: C, 58.61; H, 3.61; N, 15.03

6.1.4. 1-Aryl-3-(4-(4-substituted-phthalazin-1-yloxy)phenyl)ureas (7a-f)

General procedure:

To a stirred solution of the respective chlorophthalazine derivative **(3a,b)** (10.0 mmol, 1equiv), and cesium carbonate (6.5 g, 20.0 mmol, 2equiv) in acetonitrile (20 ml), the appropriate 1-aryl-3–(4-hydroxyphenyl)urea **(1a-c)** (10.0 mmol, 1equiv) was added and the mixture was heated under reflux for 6 h, after which TLC (CHCl₃/CH₃OH 9:1) showed no starting material. The filtrate was evaporated *in-vacuo* to afford the crude product **(7a-f)** which was further purified by column chromatography (using gradient elution starting from EtOAc then 1% MeOH/EtOAc).

6.1.4.1. 1-Phenyl-3–(4-(phthalazin-1-yloxy)phenyl)urea (7a). Yield (0.22 g; 64%), mp 180–182 °C; ¹HNMR(300 MHz, DMSO-d₆): δ 9.57 (1H, s, –NH D₂O exchangeable), δ 9.37 (1H, s, –NH D₂O exchangeable), δ 8.36 (1H, s, phthalazine), δ 8.10–8.00 (2H, m, phthalazine), δ 7.93–7.91 (2H, d, J= 7 Hz, phthalazine), δ 7.91–7.90 (2H, m, Ar-H), δ 7.49–7.47 (2H, d, J= 7.8 Hz, Ar-H), δ 7.19–7.25 (m, 3H, Ar-H), δ 6.89–6.86 (1H, d, J= 7.5 Hz, Ar-H), δ 6.67–6.65 (1H, d, J= 7.8 Hz, Ar-H); FT-IR (\dot{v} max, cm⁻¹): 3304, 3235 (2NH), 1641 (C=O); **MS** (Mwt.: 356.38): m/z 355.00 (M-1⁺, 0.11%), 146.05 (23.71%), 118.05 (8.47%), 79.95 (100.00%); Anal. Calcd for C₂₁H₁₆N₄O₂: C, 70.77; H, 4.53; N, 15.72; Found: C,71.02; H, 4.61; N, 15.89

6.1.4.2. 1–(**4**-**Chlorophenyl**)-**3**–(**4**-(**phthalazin**-**1**-yloxy)**phenyl**)**urea** (**7b**). Yield (0.19 g; 50%), mp 166–168 °C; ¹**HNMR (400 MHz, DMSO-d₆**): δ 9.72 (1H, *s*, –NH D₂O exchangeable), δ 9.44 (1H, *s*, –NH D₂O exchangeable), δ 8.37 (1H, *s*, phthalazine), δ 8.28–8.26 (2H, d, *J*=8 Hz, phthalazine), δ 8.18–8.16 (2H, d, *J*=8 Hz, phthalazine), δ 7.58–7.56 (2H, d, *J*=8.8 Hz, Ar-H), δ 7.56–7.53 (2H, d, *J*=8.8 Hz, Ar-H), δ 7.36–7.34 (2H, d, *J*=7.2 Hz, Ar-H), δ 7.14–7.12 (2H, d, *J*=7.2 Hz, Ar-H); FT-IR (\circ max, cm⁻¹): 3278, 3161 (2NH), 1701 (C=O); **MS** (Mwt.: 390.82): *m/z* 390.10 (4.47%), 365.10 (24.02%), 75.00 (100.00%);Anal. Calcd for C₂₁H₁₅ClN₄O₂: C, 64.54; H, 3.87; N, 14.34; Found: C, 64.69; H, 4.01; N, 14.62

6.1.4.3. $1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(phthalazin-1-yloxy)phenyl)urea (7c). Yield (0.22 g; 49%), mp 158–160 °C; ¹HNMR (400 MHz, DMSO-d_6): <math>\delta$ 9.91 (1H, *s*, -NH D₂O exchangeable), δ 9.08 (*s*, 1H, -NH D₂O exchangeable), δ 8.39 (*s*, 1H, phthalazine), δ 8.24–8.21 (d, J=8 Hz, 2H, phthalazine), δ 8.17–8.15 (d, J=8 Hz, 2H, phthalazine), δ 8.17–8.15 (d, J=8 Hz, 2H, phthalazine), δ 7.99 (*s*, 1H, Ar-H), δ 7.85–7.83 (d, J=7.6 Hz, 1H, Ar-H), δ 7.76–7.74 (d, J=7.6 Hz, 1H, Ar-H), δ 7.28–7.26 (d, J=8.4 Hz, 2H, Ar-H), δ 6.76–6.74 (d, J=8.4 Hz, 1H, Ar-H); ¹³CNMR (100 MHz, DMSO): δ 171.0, 153.7, 153.2, 141.1, 138.7, 133.8, 132.7, 132.0, 131.7, 129.5, 129.3, 129.1, 128.5, 127.0, 125.8, 124.7, 121.4, 121.2, 121.0, 119.6, 118.7, 115.6; FT-IR (\circ max, cm⁻¹): 3300, 3153 (2NH), 1679 (C=O); MS (Mwt: 458.82): m/z 458.10 (2.63%), 271.05 (7.73%), 195.00 (100.00%); Anal. Calcd for C₂₂H₁₄ClF₃N₄O₂: C, 57.59; H, 3.08; N, 12.21; Found: C, 57.82; H, 3.06; N, 12.57

6.1.4.4. 1–(4-(4-Methylphthalazin-1-yloxy)-3-phenylurea (7d). Yield (0.20 g; 54%), mp 174–176 °C; ¹HNMR (400 MHz, DMSO-d₆): δ

8.76 (1H, s, -NH D₂O exchangeable), δ 8.69 (1H, s, -NH D₂O exchangeable), δ 8.39–8.37 (1H, d, J=8Hz, phthalazine), δ 8.23–8.21 (1H, d, J=8Hz, phthalazine), δ 8.11–8.09 (1H, d, J=8Hz, phthalazine), δ 8.08–8.06 (1H, d, J=8Hz, phthalazine), δ 7.55–7.52 (2H, d, J=8.8Hz, Ar-H), δ 7.46–7.43 (2H, d, J=8.8Hz, Ar-H), δ 7.33–7.30 (2H, d, J=7.6Hz, Ar-H), δ 7.22–7.20 (2H, d, J=8.8Hz, Ar-H), δ 6.69–6.67 (1H, d, J=7.6Hz, Ar-H), δ 2.96 (3H, s,CH₃); FT-IR (\circ max, cm⁻¹): 3302, 3141 (2NH), 1643 (C=O); **MS** (Mwt.: 370.40): *m/z* 370.00 [M⁺, 2.28%), 277.95 (19.33%), 251.00 (100.00%); Anal. Calcd for C₂₂H₁₈N₄O₂: C, 71.34; H, 4.90; N, 15.13; Found: C, 71.49; H, 4.97; N, 15.29.

6.1.4.5. 1–(**4**-Chlorophenyl)-3–(**4**-(**4**-methylphthalazin-1-yloxy)phenyl)urea (7e). Yield (0.17 g; 42%), mp 169–171 °C; ¹HNMR (**400 MHz, DMSO-d₆**): δ 10.06 (1H, *s*, –NH D₂O exchangeable), δ 10.05 (1H, *s*, –NH D₂O exchangeable), δ 8.38–8.36 (1H, d, J=7.6 Hz, phthalazine), δ 8.20–8.18 (1H, d, J=7.6 Hz, phthalazine), δ 8.07–8.04 (2H, d, J=7.6 Hz, phthalazine), δ 7.58–7.56 (2H, d, J=8.4 Hz, Ar-H), δ 7.29–7.22 (2H, d, J=8.4 Hz, Ar-H), δ 7.20–7.18 (2H, d, J=9.2 Hz, Ar-H), δ 6.66–6.63 (2H, d, J=9.2 Hz, Ar-H), δ 2.81 (3H, *s*, CH₃); FT-IR ($\dot{\upsilon}$ max, cm⁻¹): 3300, 3153 (2NH), 1643 (C=O); **MS** (Mwt.: 404.85): *m/z* 404.90(M+, 2.04%), 385.85 (1.29%), 267.90 (4.75), 250.95 (28.16), 127.00 (100.00%); Anal. Calcd for C₂₂H₁₇ClN₄O₂: C, 65.27; H, 4.23; N, 13.84; Found: C, 65.52; H, 4.28; N, 13.97.

6.1.4.6. 1–(4-Chloro-3-(trifluoromethyl)phenyl)-3–(4-(4-metyhlph-thalazin-1-yloxy)phenyl)urea (7f). Yield (0.20 g; 42%), mp 150–152 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 10.31 (1H, s, –NH D₂O exchangeable), δ 10.30 (1H, s, –NH D₂O exchangeable), δ 8.37 (1H, s, Ar-H), δ 8.19–8.16 (2H, d, J = 8 Hz, phthalazine), δ 8.07–8.05 (1H, d, J = 7.6 Hz, Ar-H), δ 7.78–8.75 (1H,d, J = 8 Hz, phthalazine), δ 7.61–7.59 (2H, d, J = 7.6 Hz, Ar-H), δ 7.56–7.54 (1H, d, J = 8.8 Hz, Ar-H), δ 7.24–7.21(2H, d, J = 8.8 Hz, Ar-H), δ 2.80 (3H, s, CH₃); FT-IR (\circ max, cm⁻¹): 3300, 3153 (2NH), 1679 (C=O); MS (Mwt.: 472.85): *m/z* 472.80 (M+, 2.07%), 391.95 (10.86), 335.85 (25.53), 250.95 (86.76%), 194.90 (100%); Anal. Calcd for C₂₃H₁₆ClF₃N₄O₂: C, 58.42; H, 3.41; N, 11.85; Found: C, 58.49; H, 3.39; N, 12.01

6.1.5. Synthesis of ethyl 4–(4-substitutedphthalazine-1-yl)piperazine-1-carboxylate and 1-Substituted-4-(arylpiperazine-1-yl)phthalazine (8a–j)

General procedure:

To a stirred mixture of the respective 1-chlorophthalazine **(3a,b)** (10.0 mmol, 1equiv), potassium carbonate (0.27 g, 20.0 mmol, 2equiv), potassium iodide (0.01 g, 0.01 mmol, 0.1equiv) in absolute ethanol (20 ml), the respective piperazine (viz.; ethyl piperazinecarboxylate, phenylpiperazine, 2-flourophenylpiperazine, 2-pyridylpiperazine, 2-furoylpiperazine) (10.0 mmol, 1equiv) was added and the mixture was heated under reflux for 2 h, after which TLC (CHCl₃/CH₃OH 9:1) showed no starting material. The mixture was then concentrated *in vacuo*, the residue was washed with water, extracted with EtOAc, dried over anhydrous Na₂SO₄. The crude product was recrystallised from EtOAc.

6.1.5.1. Ethyl 4-(phthalazin-1-yl)piperazine-1-carboxylate (8a). Yield (0.19 g; 68%), mp 271–273 °C; ¹HNMR (300 MHz, DMSO): δ 8.10 (1H, s, phthalazine), δ 7.98–7.96 (2H, d, J = 7 Hz, phthalazine), δ 7.93–7.91 (2H, d, J = 7 Hz, phthalazine), δ 4.07 (2H, q,CH₂-CH₃), δ 3.63–3.62 (2H, m, piperazine ring), δ 2.86–2.85 (2H, m, piperazine ring), δ 2.55–2.54 (2H, m, piperazine ring), δ 2.27–2.26 (2H, m, piperazine ring), δ 1.14 (3H, t, CH₂-CH₃); ¹³CNMR (100 MHz, **DMSO**): δ 179.9, 154.9, 149.2, 134.1, 132.3, 129.6, 127.2, 123.1, 122.7, 61.6, 43.1, 41.2, 30.1, 30.0, 14.6; FT-IR ($\dot{\upsilon}$ max, cm⁻¹): 1672 (C=O); **MS** (Mwt.: 286.33): *m/z* 286.05 (M⁺, 0.95%), 270.00 (3.77%), 56.00 (100.00%); Anal. Calcd for C₁₅H₁₈N₄O₂: C, 62.92; H, 6.34; N, 19.57; Found: C, 63.23; H, 6.38; N, 19.71

6.1.5.2. 1–(4-Phenylpiperazin-1-yl)phthalazine (8b). Yield (0.20 g; 69%), mp 242–244 °C; ¹HNMR (300 MHz, DMSO): δ 9.72–7.96 (1H, s, phthalazine), δ 8.17–8.15 (1H, d, J=8Hz, phthalazine), δ 8.12–8.10 (1H, d, J=8Hz, phthalazine), δ 8.00–7.95 (2H, d, J=8Hz, phthalazine), δ 7.28–7.24 (2H, d, J=7.6Hz, Ar-H), δ 7.05–7.03 (2H, d, J=7.6Hz, Ar-H), δ 6.84–6.81 (1H, d, J=7.6Hz, Ar-H), δ 3.58–3.56 (4H, m, piperazine ring), δ 3.44–3.42 (4H, m, piperazine ring); ¹³CNMR (100 MHz, DMSO): δ 151.5, 148.2, 129.5, 128.6, 127.3, 124.3, 119.7, 116.0, 51.2, 48.7; FT-IR (\circ max, cm⁻¹): 3428 (CH aromatic), 2991, 2919 (CH aliphatic); MS (Mwt.: 290.36): m/z 290.10 (M⁺, 0.41%), 162.10 (8.10%), 120.10 (100.00%), Anal. Calcd for C₁₈H₁₈N₄: C, 74.46; H, 6.25; N, 19.30; Found: C, 74.62; H, 6.37; N, 19.54.

6.1.5.3. 1–(4-(2-Fluorophenyl)piperazin-1-yl)phthalazine (8c). Yield (0.21 g; 70%), mp 88–90 °C; ¹HNMR (300 MHz, DMSO): δ 8.61 (1H, *s*, phthalazine), δ 8.27–8.24 (2H, d, J=9Hz, phthalazine), δ 8.14–8.11 (2H, d, J=9Hz, phthalazine), δ 7.19–7.17 (1H, d, J=7.6Hz, Ar-H), δ 7.15–7.13 (1H, d, J=7.6Hz, Ar-H), δ 7.08–7.06 (1H, d, J=7.6Hz, Ar-H), δ 6.99–6.97 (1H, d, J=7.6Hz, Ar-H), δ 3.70–3.69 (2H, m, piperazine ring), δ 3.31–3.30 (2H, m, piperazine ring), δ 3.23–3.21 (4H, m, piperazine ring); ¹³CNMR (100 MHz, DMSO): δ 175.9, 159.2,145.3, 138.9, 138.3, 134.8, 134.0, 130.0, 127.6, 125.6, 123.3, 122.8, 122.7, 116.0, 50.8, 49.9, 47.0, 46.9; FT-IR (\dot{v} max, cm⁻¹): 3039 (CH aromatic), 2924 (CH aliphatic); MS (Mwt.: 308.35): m/z 308.05 (M⁺, 1.81%), 180.05 (19.88%), 138.10 (100.00%); Anal. Calcd for C₁₈H₁₇FN₄: C, 70.11; H, 5.56; N, 18.17; Found: C, 70.29; H, 5.60; N, 18.28.

6.1.5.4. 1–(**4**-(**Pyridin-2**-**y**])**piperazin-1**-**y**])**phthalazine** (**8d**). Yield (0.20 g; 69%), mp 286–288 °C; ¹**HNMR (300 MHz, DMSO**): δ 8.14–8.12 (1H, d, J=7Hz, pyridine ring), δ 7.93–7.91 (3H, m, phthalazine), δ 7.59–7.56 (2H, d, J=9Hz, phthalazine), δ 7.56–7.54 (1H, d, J=7Hz, pyridine ring), δ 6.69–6.67 (2H, d, J=7Hz, pyridine ring), δ 3.67–3.65 (4H, m, piperazine ring), δ 3.06–3.04 (4H, m, piperazine ring); FT-IR (iv max, cm⁻¹): 3030 (CH aromatic), 2926 (CH aliphatic); **MS** (Mwt.: 291.35): m/z 291.10 (M+, 0.19%), 279.05 (0.28%), 160.10 (27.24%), 95.05 (100.00); Anal. Calcd for C₁₇H₁₇N₅: C, 70.08; H, 5.88; N, 24.04; Found: C, 70.32; H, 5.64; N, 24.31

6.1.5.5. Furan-2-yl-(4-(phthalazin-1-yl)piperazin-1-yl)methanone (8e). Yield (0.23 g; 77%), mp 90–92 °C; ¹HNMR (300 MHz, DMSO): δ 8.36 (1H, s, phthalazine), δ 8.12–8.10 (1H, d, J = 7 Hz, furoyl ring), δ 8.03–8.01 (2H, d, J = 7.8 Hz, phthalazine), δ 7.98–7.96 (2H, d, J = 7.8 Hz, phthalazine), δ 6.99–6.98 (2H, d, J = 7 Hz, furoylring), δ 3.69–3.67 (4H, m,piperazine ring), δ 2.91–2.90 (4H, m, piperazine ring); ¹³CNMR (100 MHz, DMSO): δ 175.9, 159.8, 154.6, 154.2, 142.3, 135.4, 133.9, 128.5, 127.8, 125.7, 123.2, 122.2, 117.2, 111.7, 50.2, 42.8, 40.2, FT-IR ($\dot{\upsilon}$ max, cm⁻¹): 1679 (C=O); MS (Mwt.: 308.33): m/z 308.05 (M+, 4.64%), 274.00 (6.66%), 158.05 (57.70%), 95.00 (100.00%) Anal. Calcd for C₁₇H₁₆N₄O₂: C, 66.22; H, 5.23; N, 18.17; Found: C, 66.41; H, 5.32; N, 18.40

6.1.5.6. Ethyl 4–(4-methylphthalazin-1-yl)piperazine-1-carboxylate (8f). Yield (0.22 g; 73%), mp 95–97 °C; ¹HNMR (300 MHz, CDCl₃): δ 8.43–8.41 (2H, d, J=8.1 Hz, phthalazine), δ 8.36–8.34 (2H, d,

 $\begin{array}{l} J=8.1\,\text{Hz}, \text{ phthalazine}), \ \delta \ 4.19 \ (2\text{H}, \ q, \ \underline{\text{CH}_2\text{-}\text{CH}_3}), \ \delta \ 3.75\text{-}3.74 \ (4\text{H}, \\ m, \ \text{piperazine ring}), \ \delta \ 3.65\text{-}3.64 \ (4\text{H}, \ m, \ \text{piperazine ring}), \ \delta \ 3.37 \\ (3\text{H}, \ s, \ \text{CH}_3), \ \delta \ 1.33 \ (3\text{H}, \ \text{t}, \underline{\text{CH}_3\text{-}\text{CH}_2}); \ \text{FT-IR} \ (\acute{\text{v}} \ \text{max}, \ \text{cm}^{-1}): \ 1693 \\ (\text{C=O}); \ \textbf{MS} \ (\text{Mwt.: } 300.36): \ m/z \ 300.05(\text{M}+, \ 5.71\%), \ 244.05 \ (3.15\%), \\ 184.55 \ (13.85\%), \ 172.30 \ (48.47\%), \ 55.65 \ (100\%); \ \text{Anal. Calcd for} \\ \text{C}_{16}\text{H}_{20}\text{N}_4\text{O}_2: \ \text{C}, \ 63.98; \ \text{H}, \ 6.71; \ \text{N}, \ 18.65; \ \text{Found: C}, \ 64.17; \ \text{H}, \ 6.83; \\ \text{N}, \ 19.01 \end{array}$

6.1.5.7. 1-*Methyl*-**4**-(**4**-*phenylpiperazin*-1-*yl*)*phthalazine* (*8 g*). Yield (0.15 g; 56%), mp 229–231 °C; ¹HNMR (300 MHz, DMSO): δ 7.28–7.26(2H, d, J=7.2 Hz, phthalazine), δ 7.25–7.23 (2H, d, J=7.2 Hz, phthalazine), δ 6.99–6.97 (2H, d, J=7.8 Hz, Ar-H), δ 6.88–6.86 (1H, m, Ar-H), δ 6.85–6.83 (2H, d, J=7.8 Hz, Ar-H), δ 3.34–3.32 (4H, m, piperazine ring), δ 3.22–3.20 (4H, m, piperazine ring), δ 2.48 (3H, *s*, CH₃); FT-IR (\circ max, cm⁻¹): 3070 (CH aromatic), 2954 (CH aliphatic); **MS** (Mwt.: 304.39): *m*/*z* 304.00(M+, 1.73%), 284.60 (2.19%), 192.35 (5.24%), 105.20 (34.33%), 55.65 (100.00%); Anal. Calcd for C₁₉H₂₀N₄: C, 74.97; H, 6.62; N, 18.41; Found: C, 80.32; H, 6.70; N, 18.48.

6.1.5.8. 1–(**4**-(**2**-*F***Iuorophenyl)***p***i***p***e***r***a***z***i***n*-1*-***y]**)-4-*met***hy]***p***t***ht***ha***laz***i***ne* (8 *h*). Yield (0.12 g; 71%), mp 149–151 °C; ¹**HNMR (300 MHz, CDCl**₃): δ 8.15–8.13 (1H, d, J=9.6Hz, phthalazine), δ 8.05–8.01 (1H, d, J=9.6Hz, phthalazine), δ 7.87–7.83 (2H, d, J=9.6Hz, phthalazine), δ 7.07–7.04 (2H, d, J=8.7Hz, Ar-H), δ 7.01–7.00 (2H, d, J=8.7Hz, Ar-H), δ 3.69–3.67 (4H, m, piperazine ring), δ 3.39–3.36 (4H, *m*, piperazine ring), δ 2.92 (3H, s, CH₃); ¹³CNMR (100 MHz, DMSO): δ 173.5, 158. 9, 153.1, 137.4, 131.8, 131.5, 127.2, 125.2, 123.2, 123.1, 122.3, 120.4, 119.3, 116.1, 115.8, 50.9, 50.0, 47.0, 19.0, FT-IR ($\dot{\sigma}$ max, cm⁻¹): 3035 (CH aromatic), 2951 (CH aliphatic); MS (Mwt.: 322.38): *m*/z 323.50 [M + 1H]⁺ (9.74%), 172.15 (48.77%), 122.05 (100.00%); Anal. Calcd for C₁₉H₁₉FN₄: C, 70.79; H, 5.94; N, 17.38; Found: C, 71.03; H, 5.99; N, 18.48.

6.1.5.9. 1-*Methyl*-**4**-(**4**-(*pyridin*-2-*yl*)*piperazin*-1-*yl*)*phthalazine* (*8i*). Yield (0.10 g; 59%), mp 226–228 °C; ¹**HNMR (300 MHz, DMSO)**: δ 8.16–8.13(1H, d, J= 8.7 Hz, pyridyl ring), δ 7.62–7.60 (2H, d, J= 8.4 Hz, phthalazine), δ 7.58–7.56 (2H, d, J= 8.4 Hz, phthalazine), δ 6.91–6.89 (1H, d, J= 8.7 Hz, pyridyl ring), δ 6.74–6.72 (2H, d, J= 8.7 Hz, pyridyl ring), δ 3.75–3.73 (4H, m, piperazine ring), δ 3.12–3.10 (4H, m, piperazine ring), δ 2.08 (3H, *s*, CH₃); FT-IR (\circ max, cm⁻¹) 3132 (CH aromatic), 2954 (CH aliphatic); **MS** (Mwt.: 305.38): *m/z* 305.15 (M+, 1.16%), 185.65 (16.50%), 172.35 (41.23%), 55.55 (100.00%); Anal. Calcd for C₁₈H₁₉N₅: C, 70.80; H, 6.27; N, 22.93; Found: C, 71.04; H, 6.38; N, 23.18.

6.1.5.10. Furan-2-yl-(4–(4-methylphthalazin-1-yl)piperazin-1-yl) methanone (8j). Yield (0.11 g; 60%), mp 90–92°C; ¹HNMR (300 MHz, DMSO): δ 8.32–8.30 (2H, d, J=7Hz, phthalazine), δ 8.29–8.27 (2H, d, J=7Hz, phthalazine), δ 7.82–7.81 (1H, d, J=7.2Hz, furoyl ring), δ 6.97–6.96(1H, d, J=7.2Hz, furoyl ring), δ 6.62–6.60 (1H, d, J=7.2Hz, furoyl ring), δ 3.64–3.62 (4H, m, piperazine ring), δ 3.41–3.39 (4H, m, piperazine ring), δ 2.92 (3H, s, CH₃); FT-IR ($\dot{\nu}$ max, cm⁻¹): 1610 (C=O); **MS** (Mwt.: 322.36): m/z 322.00 (M+, 6.60%), 184.00 (31.70%), 172.00 (100.00%); Anal. Calcd for C₁₈H₁₈N₄O₂: C, 67.07; H, 5.63; N, 17.38; Found: C, 67.21; H, 5.69; N, 17.52.

6.1.6. Synthesis of N'-(4-chlorophthalazin-1-yl)benzene-1,4diamine (11)

General procedure:p-Phenylenediamine (0.33 g, 3.12 mmol, 3equiv) and the dichlorophthalazine (2.08 mmol, 2equiv) were treated with

2-BuOH (7.5 ml) in a tube and heated to 110 °C. The reaction quickly became a solid, yellow mass. After four hours, the reaction was cooled and diluted with water. The resultant slurry was then partitioned between equal volumes of DCM and 1 N NaOH (15 ml). The aqueous layer was extracted into DCM (2×15 ml). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The resulting orange solid was crystallised from (EtOAc/pet ether 1:1) to afford the title compound **(11)** as an orange crystals.

Yield 0.22 g, (88%); mp 170–172 °C; ¹HNMR (300 MHz, DMSOd₆): δ 13.21 (s, 1H, -NH D₂O exchangeable), 9.27 (s, 2H, 2H, -NH₂ D₂O exchangeable), δ 8.30–8.28 (d, J=7 Hz, 2H, phthalazine), δ 8.07–8.04 (d, J=7 Hz, 2H, phthalazine), δ 7.46–7.43 (d, J=9 Hz, 2H, ArH), δ 6.83–6.76 (d, J=9 Hz, 2H, ArH), δ 2.48 (s, 3H, CH₃); FT-IR (vmax, cm⁻¹): 3385 (NH₂), 3321(NH); **MS** (Mwt.: 270.72): *m/z* 250.00 (M+, 50.00%), 249.00 (100.00%), 108.00 (60.92%), 65.00 (77.59%); Anal. Calcd for C₁₄H₁₁ClN₄: C, 62.11; H, 4.10; N, 20.70; Found: C, 62.37; H, 4.18; N, 20.94.

6.1.7. Synthesis of 1-aryl-3-(4-(4-substituted phthalazin-1-ylamino) phenyl)urea (12a-c)

General procedure:

To a stirred solution of the N1-(4-chlorophthalazin-1-yl)benzene-1,4-diamine **(11)** (10.0 mmol, 1equiv) in DMF (20 ml), the respective phenyl isocyanate (viz.; phenyl isocyanate, 4-chloro phenyl isocyanate, 3-trifluromethyl-4-chlorophenyl isocyanate) (10.0 mmol, 1equiv) was added and the mixture was heated under reflux for 8–10 h, after which TLC (CH_2CI_2/CH_3OH 9:1) showed no starting material. The reaction mixture was poured over ice-water; the formed precipitate was allowed to settle, then filtered off and dried to afford the crude product **(12a-c)** which was further crystallised from EtOAc.

6.1.7.1. 1–(**4**-(**4**Chlorophthalazin-1-ylamino)phenyl)-3-phenylurea (**12a**). Yield 0.12 g; (68%), mp 225–227 °C; ¹HNMR (**400 MHz**, **DMSO-d**₆): δ 12.85 (*s*, 3H, –NH D₂O exchangeable), δ 8.63 (d, J=10 Hz 1H, phthalazine), δ 8.30–8.27 (d, J=10 Hz, 2H, phthalazine), δ 8.08–8.05 (d, J=10 Hz, 1H, phthalazine), δ 8.03–7.02 (d, J=8 Hz, 2H, Ar-H), δ 7.99–7.97 (d, J=8 Hz, 2H, Ar-H), δ 7.95–7.94 (d, J=8 Hz, 1H, Ar-H), δ 7.46–7.43 (d, J=9.2 Hz, 2H, Ar-H), δ 7.29–7.24 (d, J=9.2 Hz, 1H, Ar-H), δ 6.98–6.94 (d, J=9.2 Hz, 1H, Ar-H); ¹³**CNMR (100 MHz, DMSO)**: δ 159.0, 152.5, 146.1, 139.6, 137.0, 134.4, 132.9, 128.7, 128.3, 126.4, 125.4, 121.7, 120.5, 119.5, 118.1; FT-IR (v max, cm⁻¹): 3296, 3286, 3155 (3NH), 1668 (C=O); **MS** (Mwt.: 389.84): m/z 389.28 (M⁺, 2.84%), 367.27 (6.23%), 322.10 (11.84%), 128.10(100.00%); Anal. Calcd for C₂₁H₁₆ClN₅O: C, 64.70; H, 4.14; N, 14.96; Found: C, 64.71; H, 3.89; N, 14.52.

6.1.7.2. 1–(**4**-**Chlorophenyl**)-**3**–(**4**-(**4**-**chlorophthalazin**-**1**-ylamino)phenyl)urea (**12b**). Yield 0.20 g; (53%), mp 236–238 °C; ¹**HNMR** (**400 MHz, DMSO-d**₆): δ 12.84 (s, 2H, -NH D₂O exchangeable), δ 8.81 (s, 1H, -NH D₂O exchangeable), δ 8.29–8.27 (d, J=8.8 Hz, 1H, phthalazine), δ 8.07–8.05 (d, J=8.8 Hz, 1H, phthalazine), δ 8.02–8.00 (d, J=8.8 Hz, 1H, phthalazine), δ 7.98–7.96 (d, J=8.8 Hz, 1H, phthalazine), δ 7.95–7.94 (d, J=6.4 Hz, 2H, Ar-H), δ 7.57–7.56 (d, J=6.4 Hz, 2H, Ar-H), δ 7.48–7.47 (d, J=6.4 Hz, 2H, Ar-H), δ 7.31–7.30 (*m*, 2H, Ar-H); FT-IR (v max, cm⁻¹): 3446, 3300, 3157 (3NH), 1670 (C=O); **MS** (Mwt.: 423.07): *m/z* 424.88 [M+1H]⁺ (3.74%), 423.50 (M⁺, 9.84%), 328.27 (52.58%), 252.97 (20.15%), 119.04(100.00%); Anal. Calcd for C₂₁H₁₅Cl₂N₅O: C, 59.45; H, 3.56; N, 16.51; Found: C, 59.49; H, 3.37; N, 16.29. **6.1.7.3.** 1–(4-Chloro-3-(trifluoromethyl)phenyl)-3–(4-(4-chlorophthalazin-1-ylamino)phenyl)-urea (12c). Yield 0.22 g; (49%), mp 187–189 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 12.84 (s, 2H, –NH D₂O exchangeable), δ 9.36 (s, 1H, –NH D₂O exchangeable), δ 8.29–8.27 (d, J = 8.8 Hz, 2H, phthalazine), δ 8.27–8.25 (d, J = 8.8 Hz, 2H, phthalazine), δ 8.09 (s, 1H, Ar-H), 8.05–8.03 (d, J = 9.6 Hz, 1H, Ar-H), δ 8.01–7.97 (d, J = 9.6 Hz, 1H, Ar-H), δ 7.59–7.50 (d, J = 8.4 Hz, 2H, Ar-H), δ 7.39–7.37 (d, J = 8.4 Hz, 2H, Ar-H); FT-IR (υ max, cm⁻¹): 3387, 3344, 3290 (3NH), 1664(C=O); MS (Mwt.: 492.28): m/z 493.06 [M + 1H]⁺ (2.63%), 395.08 (32.95%), 372.90 (35.24%), 137.07 (100.00%); Anal. Calcd for C₂₂H₁₄Cl₂F₃N₅O: C, 53.68; H, 2.87; N, 14.23; Found: C, 53.72; H, 2.68; N, 14.44.

6.1.8. Synthesis of 1-aryl-3-(4-(4-chlorophthalazin-1-yloxy)phenyl)urea (13a-c)

General procedure:

To a stirred solution of 1,4 dichlorophthalazine derivative (**10**) (10.0 mmol, 1equiv), and cesium carbonate (6.5 g, 20.0 mmol, 2equiv) in acetonitrile (20 ml), the appropriate 1-aryl-3–(4-hydroxyphenyl)urea (**1a-c**) (10.0 mmol, 1equiv) was added and the mixture was heated under reflux for 6 h, after which TLC (CHCl₃/CH₃OH 9:1) showed no starting material. The solvent was evaporated under vacuum and the resultant solid was stirred with cold 1 M NaOH solution (20 ml), filtered off, dried and recrytallised from acetonitrile to afford compounds (**13a-c**).

6.1.8.1. 1-(4-(4-Chlorophthalazin-1-yloxy)phenyl)-3-phenylurea

(13a). Yield 0.12 g; (46%), mp 191–193 °C; ¹HNMR (300 MHz, DMSO-d₆): δ 10.48 (s, 1H, –NH D₂O exchangeable), δ 10.31 (s, 1H, –NH D₂O exchangeable), δ 8.46–8.44 (d, J = 8 Hz, 2H, phthalazine), δ 8.29–8.27 (d, J = 8 Hz, 2H, phthalazine), δ 7.90–7.88 (d, J = 8.6 Hz, 2H, Ar-H), δ 7.69–7.66 (d, J = 8.6 Hz, 2H, Ar-H), δ 7.40–7.37 (d, J = 8 Hz, 1H, Ar-H), δ 7.27–7.25 (d, J = 8 Hz, 2H, Ar-H), δ 6.94–6.92 (d, J = 8 Hz, 2H, Ar-H); ¹³CNMR (100 MHz, DMSO): δ 164.7, 158.8, 153. 8, 152.4, 141.3, 136.6, 135.3, 132.3, 128.4, 128.0, 127.3, 125. 7, 123.8, 121.6, 120.6, 120.2, 118.1, 115.1; FT-IR (ν max, cm⁻¹): 3325, 3295 (2NH), 1662 (C=O); MS (Mwt.: 390.82): m/z 390.97.00 (M⁺, 2.24%), 346.01 (5.06%), 268.11 (18.11%), 179.11 (100.00%); Anal. Calcd for C₂₁H₁₅ClN₄O₂: C, 64.54; H, 3.87; N, 14.43; Found: C, 64.97; H, 4.21; N, 14.12.

6.1.8.2. 1–(**4**-*C***hlorophenyl)-3–(4-(4-chlorophthalazin-1-yloxy)phenyl)urea (13b). Yield 0.19 g; (50%), mp 172–174 °C; ¹HNMR (400 MHz, DMSO-d₆): \delta 9.06 (s, 1H, –NH D₂O exchangeable), \delta 8.54 (s, 1H,–NH D₂O exchangeable), \delta 8.34–8.32 (d, J=8.4 Hz, 2H, phthalazine), \delta 8.18–8.16 (d, J=8.4 Hz, 2H, phthalazine), \delta 7.44–7.42 (d, J=8.8 Hz, 2H, Ar-H), \delta 7.35–7.33 (d, J=8.8 Hz, 2H, Ar-H), \delta 7.27–7.25 (d, J=7.2 Hz, 2H, Ar-H), \delta 6.78–6.76 (d, J=7.2 Hz, 2H, Ar-H); FT-IR (\nu max, cm⁻¹): 3278, 3155 (2NH), 1666 (C=O); MS (Mwt.: 425.27):** *m/z* **425.28 (M⁺, 5.29%), 305.13 (7.74%), 201.08 (11.73%), 63.03 (100.00%); Anal. Calcd for C₂₁H₁₄Cl₂N₄O₂: C, 59.31; H, 3.32; N, 13.17; Found: C, 59.62; H, 3.60; N, 13.65.**

6.1.8.3. 1–(**4**-Chloro-3-(trifluoromethyl)phenyl)-3–(**4**-(phthalazin-1yloxy)phenyl)urea (13c). Yield 0.22 g; (49%), mp 210–212 °C; **¹HNMR (400 MHz, DMSO-d**₆): δ 10.20 (s, 1H, –NH D₂O exchangeable), δ 10.13 (s, 1H, –NH D₂O exchangeable), δ 8.28–8.26 (d, J=9 Hz, 2H, phthalazine), δ 8.25–8.23 (d, J=9 Hz, 2H, phthalazine), δ 8.09 (s, 1H, Ar-H), δ 7.93–7.92 (d, J=7.6 Hz, 1H, Ar-H), δ 7.76–7.74 (d, J=7.6 Hz, 1H, Ar-H), δ 7.54–7.51 (d, J=8.4 Hz, 2H, Ar-H), δ 6.69–6.66 (d, J = 8.4 Hz, 2H, Ar-H); FT-IR (υ max, cm $^{-1}$): 3294, 3155(2NH), 1662 (C=O); **MS** (Mwt.: 493.27): 493.46 (M^+, 1.24%), 281.00 (2.26%), 194.97(100.00%); Anal. Calcd for C₂₂H₁₃Cl₂F₃N₄O₂: C, 53.57; H, 2.66; N, 11.36; Found: C, 53.81; H, 2.90; N, 11.3.

6.1.9. Synthesis of N-(4-chlorophenyl)-4-methylphthalazin-1amine (14)

General procedure:

To a stirred mixture of the 1-chloro-4-methyl-phthalazine **(3b)** (1.78, 10.0 mmol, 1 equiv) in butanol (50 ml), triethylamine (1 ml, 10.0 mmol, 1 equiv) the respective amine (viz.; aniline, p-Cl aniline) (10.0 mmol, 1 equiv) was added and the mixture was heated under reflux for 2 h, after which TLC (CHCl₃/CH₃OH 9:1) showed no starting material. The mixture was then concentrated *in vacuo*, the crude product was recrystallised from methanol.

Yield 1.56 g; (88%), mp 213–215 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H, –NH D₂O exchangeable), δ 9.10–9.07 (d, J=9Hz, 1H, phthalazine), δ 8.45 –8.44 (d, J=9Hz, 1H, phthalazine), δ 8.31–8.29 (d, J=9Hz, 1H, phthalazine), δ 8.33–8.20 (d, J=9Hz, 1H, phthalazine), δ 7.85–7.82 (d, J=8Hz, 1H, Ar-H) , δ 7.51–7.49 (d, J=8Hz, 1H, Ar-H), δ 7.10–7.07 (d, J=8Hz, 1H, Ar-H), δ 6.70–6.68 (d, J=8Hz, 1H, Ar-H) , δ 2.97 (s, 3H, CH₃); FT-IR (v max, cm⁻¹) 3360 (NH), 3050 (CH aromatic); **MS** (Mwt.: 269.73): m/z 269.28 (M⁺, 8.26%), 239.18 (15.43%), 125.22 (24.70%), 90.97(100.00%); Anal. Calcd for C₁₅H₁₂ClN₃: C, 66.79; H, 4.48; N, 15.58; Found: C, 67.03; H, 4.57; N, 15.75.

6.1.10. Synthesis of 4-(bromomethyl)-N-(4-chlorophenyl)phthalazin-1-amine (15)

General procedure:

A mixture of the N-aryl-4-methylphthalazin-1-amine (**14b**) (0.26 mmol, 1 equiv), N-bromo-succinimide (4.6 g, 0.26 mmol, 1 equiv) and dibenzoyl peroxide (0.44 g, 0.018 mmol, 0.07 equiv) in carbon tetrachloride (150 ml) was refluxed for 24 h. The reaction mixture was cooled to 40 °C, and then filtered. The filtrate was concentrated under vacuum to afford the crude product, which was triturated with ether to give a yellowish solid product.

Yield 0.10 g; (42%), mp 172.-174 °C; ¹**HNMR** (400 MHz, DMSOd₆): δ 11.06 (*s*, 1H, -NH D₂O exchangeable), δ 8.07-8.05 (d, J=7.2 Hz, 2H, phthalazine), δ 7.99 -7.97 (d, J=7.2 Hz, 2H, phthalazine), δ 7.62-7.60 (d, J=7.6 Hz, 2H, Ar-H), δ 7.45-7.44 (d, J=7.6 Hz, 2H, Ar-H), δ 4.02 (s, 2H, CH₂); FT-IR (v max, cm⁻¹) 3450 (NH), 3053 (CH aromatic); **MS** (Mwt.: 348.62): m/z 350.00 (M⁺², 2.86%), 348.00 (M⁺, 9.89%), 268.04 (65.94), 102.03 (100.00%); Anal. Calcd for C₁₅H₁₁BrClN₃: C, 51.68; H, 3.18; N, 12.05; Found: C, 51.90; H, 3.16; N, 12.18.

6.1.11. Synthesis of N-(4-chlorophenyl)-4-(3-substitutedphenylamino)methyl)phthalazin-1-amines (16a-d)

General procedure:

To a stirred solution of 4-(bromomethyl)-N-(4-chlorophenyl)phthalazin-1-amine (**15**) (10.0 mmol, 1 equiv), potassium carbonate (0.27 g, 20.0 mmol, 2equiv), potassium iodide (0.01 g, 0.01 mmol, 0.1equiv) in acetone (20 ml), the respective amine (viz.; aniline, m-Chloroaniline, m-touilidine, m-anisidine) (10.0 mmol, 1equiv) was added and the mixture was heated under reflux for 4–6 h, after which TLC (CH₂Cl2/CH₃OH 99:1) showed no starting material. The mixture was then filtered and the filtrate concentrated *in vacuo*, the residue was crystallised from acetone. **6.1.11.1.** *N*-(4-Chlorophenyl)-4-((phenylamino)methyl)phthalazin-1amine (16a). Yield 0.10 g; (42%), mp 120–122 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 11.03 (s, 1H, –NH D₂O exchangeable), δ 9.65 (s, 1H, –NH D₂O exchangeable), δ 8.75–8.72 (d, *J*=9.2 Hz, 2H, phthalazine), δ 8.28 –8.25 (d, *J*=9.2 Hz, 2H, phthalazine), δ 7.90–7.88 (d, *J*=8.6 Hz, 2H, Ar-H), δ 7.85–7.87 (d, *J*=8.6 Hz, 2H, Ar-H), δ 7.46–7.43 (d, *J*=7.6 Hz, 1H, Ar-H), δ 7.05–7.03 (d, *J*=7.6 Hz, 2H, Ar-H), δ 6.83–6.81 (d, *J*=7.6 Hz, 2H, Ar-H), δ 3.89 (s, 2H, CH₂); FT-IR (v max, cm⁻¹) 3446, 3383 (2NH), 3068 (CH aromatic), 2976 (CH aliphatic); **MS** (Mwt.: 360.84): *m/z* 360.02 (M^{+,} 2.87%), 345.88 (13.64%), 268.02 (49.93%), 75.01 (100%); Anal. Calcd for C₂₁H₁₇ ClN₄: C, 69.90; H, 4.75; N, 15.53; Found: C, 70.12; H, 4.82; N, 15.69.

6.1.11.2. *N*-(4-Chlorophenyl)-4-((3-chlorophenylamino)methyl)phthalazin-1-amine (16b). Yield 0.10 g; (42%), mp 164–166 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 9.90 (s, 2H, –NH D₂O exchangeable), δ 8.86–8.84 (d, J=9.2 Hz, 2H, phthalazine), δ 8.34 –8.32 (d, J=9.2 Hz, 2H, phthalazine), δ 8.20–8.18 (d, J=8.6 Hz, 2H, Ar-H), δ 8.12–8.09 (d, J=8.6 Hz, 2H, Ar-H), δ 7.88–7.86 (d, J=7.6 Hz, 1H, Ar-H), δ 7.53–7.51 (d, J=7.6 Hz, 1H, Ar-H), δ 7.44–7.42 (d, J=7.6 Hz, 2H, Ar-H), δ 3.79 (s, 2H, CH₂); FT-IR (v max, cm⁻¹) 3379 (2NH), 3080 (CH aromatic), 2954 (CH aliphatic); **MS** (Mwt.: 395.28) *m/z* 395.99 (M^{+,} 2.17%), 271.01 (16.80%), 268.01 (100%); Anal. Calcd for C₂₁H₁₆Cl₂N₄: C, 63.81; H, 4.08; N, 14.17; Found: C, 63.94; H, 4.12; N, 14.28.

6.1.11.3. *N*-(4-Chlorophenyl)-4-((*m*-tolylamino)methyl)phthalazin-1amine (16c). Yield 0.10 g; (42%), mp 130–132 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 9.70 (s, 2H, –NH D₂O exchangeable), δ 8.86–8.84 (d, J=9.2 Hz, 2H, phthalazine), δ 8.34 –8.32 (d, J=9.2 Hz, 2H, phthalazine), δ 8.20–8.18 (d, J=8.6 Hz, 2H, Ar-H), δ 8.12–8.09 (d, J=8.6 Hz, 2H, Ar-H), δ 7.58–7.86 (d, J=7.6 Hz, 1H, Ar-H), δ 7.53–7.51 (d, J=7.6 Hz, 1H, Ar-H), δ 7.44–7.42 (d, J=7.6 Hz, 2H, Ar-H), δ 3.79 (s, 2H, CH₂), δ 2.69 (s, 3H, CH₃);): ¹³CNMR (100 MHz, DMSO): δ 162.2, 152.9, 151.1, 138.9, 135.0, 133.8, 131.7, 127.3, 127.1, 126.8, 126.4, 126.3, 124.7, 124.3, 124.1, 120.5, 120.2, 117.4, 113.2, 110.5, 45.5, 16.7, FT-IR (ν max, cm⁻¹) 3446, 32992 (2NH), 3050 (CH aromatic), 2922 (CH aliphatic); MS (Mwt.: 374.13): m/z 374.75 (M^{+,} 2.65%), 268.06 (21.45%), 189.95 (18.36%), 77.06 (100%); Anal. Calcd for C₂₂H₁₉CIN₄: C,70.49; H, 5.11; N, 14.95; Found: C, 70.73; H, 5.19; N, 15.08.

6.1.11.4. N-(4-Chlorophenyl)-4-((3-methoxyphenylamino)methyl)ph*thalazin-1-amine* (16d). Yield 0.10 g; (42%), mp 175–177 °C; ¹**HNMR (400 MHz, DMSO-d₆)**: δ 11.34 (s, 1H, –NH D₂O exchangeable), δ 9.78 (s, 1H, -NH D₂O exchangeable), δ 8.73-8.70 (d, J = 9.6 Hz, 2H, phthalazine), δ 8.48 –8.46 (d, J = 9.6 Hz, 2H, phthalazine), δ 8.06–8.04 (d, J = 8.6 Hz, 2H, Ar-H), δ 7.87–84 (d, J = 8.6 Hz, 2H, Ar-H), δ 7.68–7.66 (d, J=7.5 Hz, 1H, Ar-H), δ 7.46–7.44 (d, J = 7.5 Hz, 2H, Ar-H), δ 7.14–7.12 (d, J = 7.5 Hz, 1H, Ar-H), δ 4.29 (s, 2H, CH₂), δ 3.63 (s, 3H, OCH₃); ¹³CNMR (100 MHz, DMSO): δ 164.2, 163.9, 148.7, 148.8, 139.2, 132.3, 131.3, 129.6, 128.5, 127.9, 123.19, 122.1, 120.4, 120.4, 115.1, 110.3, 109.2, 106.0, 105.7, 105.0, 51.2, 45.7;FT-IR (v max, cm⁻¹) 3412, 3385 (2NH), 3041(CH aromatic), 2976 (CH aliphatic); MS (Mwt.: 390.87): m/z 391.95 (M+, 7.73%), 350.00 (29.42%), 348.01 (100.00%), 313.04 (10.74%); Anal. Calcd for C₂₂H₁₉ ClN₄O: C, 67.60; H, 4.90; N, 14.33; Found: C, 67.91; H, 4.95; N, 14.50.

6.1.12. Synthesis of N-(4-chlorophenyl)-4-(aryloxymethyl)phthalazin-1-amine (17a,b)

General procedure:

To a stirred solution of 4-(bromomethyl)-N-(4-chlorophenyl)phthalazin-1-amine (**15**) (10.0 mmol, 1 equiv), sodium hydride (0.27 g, 20.0 mmol, 2equiv) in acetone (20 ml), the respective phenol (viz.; phenol, m-cresol) (10.0 mmol, 1equiv) was added and the mixture was heated under reflux for 6–8 h, after which TLC (CH_2CI_2/CH_3OH 99:1) showed no starting material. The mixture was then filtered and the filtrate concentrated *in vacuo*, the residue was crystallised from acetone.

6.1.12.1. *N*-(4-Chlorophenyl)-4-(phenoxymethyl)phthalazin-1-amine (17a). Yield 0.10 g; (42%), mp 242–244 °C; ¹HNMR (400 MHz, **DMSO-d₆**): δ 9.33 (s, 1H,–NH D₂O exchangeable), δ 8.74–8.75 (d, J = 9.2 Hz, 2H, phthalazine), δ 8.30 –8.28 (d, J = 9.2 Hz, 2H, phthalazine), δ 8.11–8.09 (d, J = 8.6 Hz, 2H, Ar-H), δ 7.89–7.87 (d, J = 8.6 Hz, 2H, Ar-H), δ 7.49–7.47 (d, J = 7.6 Hz, 2H, Ar-H), δ 7.17–7.15 (d, J = 7.6 Hz, 1H, Ar-H), δ 6.76–6.74 (d, J = 7.6 Hz, 2H, Ar-H), δ 3.89 (s, 2H, CH₂); FT-IR (v max, cm⁻¹) 3379 (NH), 3066 (CH aromatic), 2978 (CH aliphatic); **MS** (Mwt.: 361.82): *m/z* 361.00 (M⁺, 5.29%), 349.01 (17.15%), 310.24 (12.19%), 268.11 (64.63%), 133.44 (100.00%); Anal. Calcd for C₂₁H₁₆ClN₃O: C, 69.71; H, 4.46; N, 11.61; Found: C, 69.88; H, 4.39; N, 11.69.

6.1.12.2. N-(4-Chlorophenyl)-4-(m-tolyloxymethyl)phthalazin-1*amine* (*17b*). Yield 0.10 g; (42%), mp 193–195 °C; ¹HNMR (400 MHz, DMSO-d₆): δ 9.33 (s, 1H,–NH D₂O exchangeable), δ 8.74–8.72 (d, J = 8.8 Hz, 2H, phthalazine), δ 8.31–8.28 (d, J = 8.8 Hz, 2H, phthalazine), δ 8.14–8.11 (d, J=8.6 Hz, 2H, Ar-H), δ 8.09–8.06 (d, J = 8.6 Hz, 2H, Ar-H), δ 7.49–7.47 (d, J = 7.6 Hz, 1H, Ar-H), δ 7.47–7.44 (d, J = 8.6 Hz, 2H, Ar-H), δ 6.55–6.53 (d, J = 8.6 Hz, 1H, Ar-H), δ 3.89 (s, 2H, CH₂), δ 2.19 (s, 3H, CH₃); ¹³CNMR (100 MHz, **DMSO**): δ 173.4, 162.4, 151.0, 139.4, 138.4, 133.1, 132.1, 128.9, 128.6, 128.4, 126.9, 126.9, 125.9, 123.3, 123.15, 121.9, 119.4, 115.7, 112.2, 75.4, 20.9, FT-IR (v max, cm⁻¹) 3414 (NH), 3034 (CH aromatic), 2976 (CH aliphatic); MS (Mwt.: 375.85): m/z 375.94 (M+, 1.09%), 349.94 (4.65%), 267.15 (100.00%); Anal. Calcd for C22H18CIN3O: C, 70.30; H, 4.83; N, 11.18; Found: C, 70.43; H, 4.88; N, 11.32.

Acknowledgements

The authors are grateful to The National Cancer Institute, Maryland, USA for performing anticancer activity. TMI would like to acknowledge Prof. Frank Boeckler (University of Tuebingen, Germany) for granting access to XBScore and to some functions of MOE.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

- Zhang YS, Liu Y, Chen D, et al. Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives. Eur. J. Med. Chem 2010;45:3504–10.
- Imramovský A, Jorda R, Pauk K, et al. Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines. Eur J Med Chem 2013;68:253–9.

- 3. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ 2001;322:1536–8.
- 4. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39.
- Cortes E, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol 2013; 50:271–83.
- 6. Scott EN, Meinhardt G, Jacques C, et al. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 2007;16: 367–79.
- 7. Hasinoff BB, Pate D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes *in vitro*. Toxicol Appl Pharm 2010;249:132–9.
- 8. Ricci MS, Kim SH, Ogi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66–80.
- 9. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851–8.
- 10. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808–18.
- Chuma M, Terashita K, Sakamoto N. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatol Res 2015;45:E1–11.
- 12. Blanc J, Geney R, Menet C. Type II kinase inhibitors: an opportunity in cancer for rational design. Anticancer Agents Med Chem 2013;13:731–47.
- 13. Sodani K, Patel A, Anreddy N, et al. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol 2014;89:52–61.
- 14. Garuti L, Roberti M, Bottegoni G. Small molecule aurora kinases inhibitors. Curr Med Chem 2009;16:1949–63.
- 15. Shallal HM, Russu WA. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. Eur J Med Chem 2011;46:2043–57.
- Rice KD, Kim MH, Bussenius J, et al. Pyrazolopyrimidines as dual Akt/p70S6K inhibitors. Bioorg Med Chem Lett 2012;22: 2693–7.
- 17. Pollard JR, Mortimore M. Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 2009;52:2629–51.
- 18. Musumeci F, Radi M, Brullo C, Schenone S. Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. J Med Chem 2012;55:10797–822.
- 19. Abouzid KM, Khalil N, Ahmed E. Synthesis and evaluation of anti-proliferative activity of 1,4-disubstituted phthalazines. Med Chem Res 2012;21:3288–93.

- 20. Sammond DM, Veal JM, Nolte RT, et al. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorg Med Chem Lett 2005;15:3519–23.
- 21. Stout DM, Matier WL, Barcelon-Yang C, et al. Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 3. Modifications to the linkage region (region 3). J Med Chem 1985;28:295–8.
- 22. Nakatsu MN, Sainson RCA, Aoto JN, et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvas Res 2003;66: 102–12.
- 23. Park H-J, Zhang Y, Georgescu SP, et al. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev 2006;2:93–101.
- 24. Alley MC, Monks A, Hursey ML, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589–601.
- 25. Grever MR, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992;19:622–38.
- 26. Jiang BH, Jiang G, Zheng JZ, et al. Phosphatidylinositol 3kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth 2001;12:363–9.
- 27. C, Behl C, Ziegler Cell aging: molecular mechanisms and implications for disease. 1st ed. Berlin Heidelberg: Springer-Verlag; 2014.
- 28. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31: 455–61.
- 29. Wilcken R, Zimmermann MO, Lange A, et al. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem 2013;56:1363–88.
- 30. Wilcken R, Zimmermann MO, Lange A, et al. Addressing methionine in molecular design through directed sulfurhalogen bonds. J Chem Theory Comput 2011;7:2307–15.
- 31. Zimmermann MO, Lange A, Boeckler FM. Evaluating the potential of halogen bonding in molecular design: automated scaffold decoration using the new scoring function XBScore. J Chem Inf Model 2015;55:687–99.
- Smolyar NN, Yutilov YM. Cyclotransformation in the series of fused 5-nitropyridin-2(1H)-ones. Russ J Org Chem 2008;44: 274–81.
- 33. Gabriel S, Neumann A. Umlagerung von Phtalidderivatenin AbkÖmmlinge des $\alpha \gamma$ Diketohydrindens. Chemische Berichte 1893;26:708–9.
- 34. Zhang QR, Xue DQ, He P, et al. Synthesis and antimicrobial activities of novel 1,2,4-triazolo [3,4-a] phthalazine derivatives. Bioorg Med Chem Letters 2014;24:1236–8.